

12-17-99

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>	<i>Attorney Docket No.</i>	13765-726	<i>Total Pages</i>	62
	<i>First Named Inventor or Application Identifier</i>			
	Michael R. Stallcup, Ph.D.			
	<i>Express Mail Label No.</i>	EI926015554US		

jc675 U.S. PTO
09/444377

12/15/99

APPLICATION ELEMENTS <i>(See MPEP chapter 600 concerning utility patent application contents:</i>		Assistant Commissioner for Patents ADDRESS TO: Box Patent Application Washington, DC 20231		
<p>1. <input type="checkbox"/> Fee Transmittal Form <i>(Submit an original, and a duplicate for fee processing)</i></p> <p>2. <input checked="" type="checkbox"/> Specification (preferred arrangement set forth below) [Total Pages 51]</p> <p>X - Descriptive title of the Invention</p> <p>- Cross References to Related Applications</p> <p>- Statement Regarding Fed sponsored R & D</p> <p>- Reference to Microfiche Appendix</p> <p>- Background of the invention</p> <p>X - Brief Summary of the Invention</p> <p>X - Brief Description of the Drawings (if filed)</p> <p>- Detailed Description</p> <p>X - Claim(s)</p> <p>X - Abstract of the Disclosure</p>		<p>6. <input type="checkbox"/> Microfiche Computer Program (Appendix)</p> <p>7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)</p> <p>a. <input type="checkbox"/> Computer Readable Copy</p> <p>b. <input type="checkbox"/> Paper Copy (identical to computer copy)</p> <p>c. <input type="checkbox"/> Statement verifying identity of above copies</p>		
<p>3. <input checked="" type="checkbox"/> Drawings (35 USC 113) [Total Sheets 11]</p> <p>4. Oath or Declaration [Total Pages]</p> <p>a. <input type="checkbox"/> Newly executed (original or copy)</p> <p>b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 17 completed)</i></p> <p>i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)</p> <p>5. <input type="checkbox"/> Incorporated By Reference (useable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.</p>		<p>8. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))</p> <p>9. <input type="checkbox"/> 37 CFR 3.73(b) Statement (when there is an assignee) <input type="checkbox"/> Power of Attorney</p> <p>10. <input type="checkbox"/> English Translation Document (if applicable)</p> <p>11. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>12. <input type="checkbox"/> Preliminary Amendment</p> <p>13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i></p> <p>14. <input type="checkbox"/> Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application, Status still proper and desired</p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document (s) <i>(if foreign priority is claimed)</i></p> <p>16. <input type="checkbox"/> Other:</p>		
<p>17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:</p> <p><input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: /</p>		<p>18. CORRESPONDENCE ADDRESS</p> <p><input type="checkbox"/> Customer Number or Bar Code Label <input type="checkbox"/> (Insert Customer No. or Attach Bar code label here) or <input checked="" type="checkbox"/> Correspondence address below</p>		

NAME	Vincent K. Yip, Registration No. 42,245				
SIGNATURE	<i>Vincent Yip</i>				
ADDRESS	McCutchen, Doyle, Brown & Enersen LLP, Three Embarcadero Center				
CITY	San Francisco	STATE	California	ZIP CODE	94111
COUNTRY	USA	TELEPHONE	(415) 393-2000	FAX	(415) 393-2286

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application for Patent

on:

5 **REGULATION OF GENE EXPRESSION BY PROTEIN METHYLATION**

by:

Michael R. Stallcup

Dagang Chen

Heng Hong

10 Dana W. Aswad

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE**RELATED APPLICATION DATA**

This application claims priority to provisional application Serial No. 60/112,523
15 filed December 15, 1998, the entire disclosure of which is herein incorporated by reference.

GOVERNMENT SUPPORT

The government may have certain rights in this invention pursuant to grants
DK43093 and NS17269 from the National Institutes of Health.

FIELD OF THE INVENTION

20 The invention relates to coactivators of transcription and to proteins with protein
methyltransferase activity.

BACKGROUND

The activities of all cells are conducted primarily by the thousands of different
types of proteins each cell produces. The blueprint or code for synthesizing each protein is found
25 in a corresponding gene, i.e., each gene encodes the information needed to synthesize a specific

protein. Gene “expression” results in the production of the protein by a stepwise mechanism that includes 1) “transcription” of the gene by RNA polymerase to produce a messenger RNA (mRNA) that contains the same protein-encoding information; and 2) “translation” of the mRNA by ribosomes to produce the protein. Each gene is expressed in specific tissues and at specific times during the life of the organism. Expression of most genes is regulated in response to a variety of signals that arise either outside or inside the organism. This pattern of specific expression for each gene is determined by the “promoter region” of each gene, which is located adjacent to the protein-encoding region of the gene. Each gene’s promoter contains many “regulatory elements.” Each regulatory element serves as a binding site for a specific protein, and the binding of the appropriate protein to a specific regulatory element can cause enhancement or repression of gene expression. Together, the regulatory elements and the proteins that bind to these elements determine the expression pattern for the specific gene.

Hormones represent one of the most important mechanisms for communication between different organs and tissues in multicellular organisms. In mammals, hormones are synthesized in one organ or tissue, and travel through the blood stream to various target organs. By interacting with specific receptor proteins in the target cells, the hormones change the activities of the cell. Frequently the cellular effects of the hormone include changes in the expression of specific genes. The protein products of these genes then carry out the biological actions that result in altered cellular functions.

The effects of one extremely important class of hormones are carried out by a family of related receptor proteins called the nuclear receptors (Evans, R.M. (1988) *Science* 240:889-895; Tsai, M-J. and B.W. O’Malley (1994) *Annu. Rev. Biochem.* 63:451-486; Beato, M., et al. (1995) *Cell* 83:851-857). This family of proteins includes the receptors for all of the steroid hormones, thyroid hormones, vitamin D, and vitamin A, among others. The family also includes a large number of proteins called “orphan receptors” because they do not bind any hormone or because the hormone that binds to them is unknown; but they are nevertheless structurally and functionally related to the hormone-binding nuclear receptors. Nuclear receptors are transcriptional regulatory proteins that act by a common mechanism. For those nuclear receptors that do bind hormones, the appropriate hormone must enter the cell and bind to the

nuclear receptors, which are located inside the target cells. The activated nuclear receptors bind to specific regulatory elements associated with specific genes that are regulated by these proteins. Binding of the activated nuclear receptors to the regulatory elements helps to recruit RNA polymerase to the promoter of the gene and thereby activates expression of the gene. This mechanism also applies to many of the orphan nuclear receptors.

- After nuclear receptors bind to a specific regulatory element in the promoter of the gene, they recruit RNA polymerase to the promoter by a mechanism which involves another group of proteins called coactivators, that are recruited to the promoter by the nuclear receptors (Horwitz, K.B. *et al.* (1996) *Mol. Endocrinol.* **10**:1167-1177; Glass, C.K. *et al.* (1997) *Curr. Opin. Cell Biol.* **9**:222-232). The complex of coactivators helps the receptors to activate gene expression by two different mechanisms: 1) they make the gene more accessible to RNA polymerase by unfolding the “chromatin.” Chromatin is composed of the DNA (which contains all the genes) and a large group of DNA-packaging proteins. To unfold chromatin some of the coactivator proteins contain an enzymatic activity known as a histone acetyltransferase (HAT). 15 HAT proteins transfer an acetyl group from acetyl CoA to the major chromatin proteins, which are called “histones.” Acetylation of the histones helps to unfold chromatin, thus making the gene and its promoter more accessible to RNA polymerase. 2) The coactivators and the nuclear receptors make direct contact with a complex of proteins called basal transcription factors that are associated with RNA polymerase; this interaction recruits RNA polymerase to the promoter. 20 Once RNA polymerase binds to the promoter, it initiates transcription, i.e., synthesis of mRNA molecules. The final activation of RNA polymerase after it binds to the promoter may also require some intervention by the coactivator proteins, but little is known about the mechanism of these final steps of transcriptional activation.

One specific family of three related coactivator proteins, the “nuclear receptor coactivators” or “p160 coactivators” (because their mass is approximately 160 kilodaltons), are required for the gene activation activities of many of the nuclear receptor proteins. The three related nuclear receptor coactivators are GRIP1, SRC-1, and p/CIP; all three proteins also have additional names that are used by some investigators (Onate, S.A. *et al.* (1995) *Science* **270**:1354-1357; Hong, H. *et al.* (1996) *Proc. Natl. Acad. Sci. USA* **93**:4948-4952; Voegel, J.J. *et al.* (1996) *EMBO J.* **15**:3667-3675; Kamei, Y. *et al.* (1996) *Cell* **85**:403-414; Torchia, J. *et al.*

(1997) *Nature* **387**:677-684; Hong, H. *et al.* (1997) *Mol. Cell. Biol.* **17**:2735-2744; Chen, H. *et al.* (1997) *Cell* **90**:569-580; Anzick, S.L. *et al.* (1997) *Science* **277**:965-968; Li, H. *et al.* (1997) *Proc. Natl. Acad. Sci. USA* **94**:8479-8484; Takeshita, A. *et al.* (1997) *J. Biol. Chem.* **272**:27629-27634). These coactivators are recruited directly by the DNA-bound nuclear receptors. The 5 nuclear receptor coactivators, in turn, recruit other coactivators, including CBP (or p300) and p/CAF (Chen, H. *et al.* 1997). All of these coactivators have been shown to play roles in gene activation by one or both of the two mechanisms mentioned above. Some of them have HAT activities to help unfold chromatin structure (Chen, H. *et al.* 1997; Spencer, T.E. *et al.* (1997) *Nature* **389**:194-198), and others have been shown to make direct contact with proteins in the 10 RNA polymerase complex (Chen, H. *et al.* 1997; Swope, D.L. *et al.* (1996) *J. Biol. Chem.* **271**:28138-28145). Thus, the discovery and characterization of these coactivators provides a better understanding of the mechanism by which nuclear receptors activate gene transcription.

Histones are known to be methylated as well as acetylated (Annunziato, A.T. *et al.* (1995) *Biochem.* **34**:2916; Gary J.D. and Clarke, S. (1998) *Prog. Nucleic Acids Res. Mol. Biol.* **61**:65). However, the function of histone methylation is unknown. Methylation of histone H3, is a dynamic process during the lifetime of histone molecules, and newly methylated H3 is preferentially associated with chromatin containing acetylated H4 (Annunziato, A.T. *et al.* 1995); thus methylation of H3, like acetylation of H4, is associated with active chromatin. In other studies lysine methylation of histones has been found in a variety of organisms; arginine 15 methylation of histones, while not clearly documented in mammals, has been demonstrated in other classes of organisms (Gary and Clarke 1998). In *Drosophila* cells heat shock treatment causes increased arginine methylation of histone H3, which could be associated with activation of heat shock genes or repression of the other genes (Desrosiers, R. and R.M. Tanguay (1988) *J. Biol. Chem.* **263**:4686).

20 Proteins can be N-methylated on amino groups of lysines and guanidino groups of arginines or carboxymethylated on aspartate, glutamate, or the protein C-terminus. Recent 25 studies have provided indirect evidence suggesting roles for methylation in a variety of cellular processes such as RNA processing, receptor mediated signaling, and cellular differentiation (Aletta, J.M. *et al.* (1998) *Trends Biochem. Sci.* : **23**:89; Gary and Clarke 1998). However, for the

most part the specific methyltransferases, protein substrates, and specific roles played by methylation in these phenomena have not been identified. Two types of arginine-specific protein methyltransferase activities have been observed, type I and type II. Genes for three mammalian and one yeast type I enzymes, which produce monomethyl and asymmetric dimethylarginine residues previously have been identified (Figure 1). On the other hand, type II protein arginine methyltransferases produce monomethyl and symmetric dimethylarginine residues. *In vitro* protein substrates for various protein arginine methyltransferases include histones and proteins involved in RNA metabolism such as hnRNPA1, fibrillarin, and nucleolin (Lin, W-J. *et al.* (1996) *J. Biol. Chem.* **271**:15034-15044.; Gary, J.D. *et al.* (1996) *J. Biol. Chem.* **271**:4585; Najbauer, J. *et al.* (1993) *J. Biol. Chem.* **268**:10501-10509). The arginine residues methylated in many of these proteins are found in glycine-rich sequences, and synthetic peptides mimicking these sequences are good substrates for the same methyltransferases (Najbauer, J. *et al.* 1993).

SUMMARY

The invention relates to a transcriptional coactivator, Coactivator Associated arginine (R) Methyltransferase (CARM1).

One aspect of the invention includes CARM1 cDNA polynucleotides such as (SEQ ID NO: 1). Polynucleotides include those with sequences substantially equivalent to SEQ ID NO: 1, including fragments thereof. Polynucleotides of the present invention also include, but are not limited to, a polynucleotide complementary to the nucleotide sequence of SEQ ID NO: 1.

Polynucleotides according to the invention have numerous applications in a variety of techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization probes, use as oligomers, i.e. primers for PCR, use for chromosome and gene mapping, use in the recombinant production of protein, and use in generation of antisense DNA or RNA, their chemical analogs and the like. For example, when the expression of an mRNA is largely restricted to a particular cell or tissue type, polynucleotides of the invention can be used as hybridization probes to detect the presence of the specific mRNA in the particular cell or tissue RNA using, e.g., *in situ* hybridization. The invention also includes vectors encoding the polynucleotides of the invention.

The invention also describes the deduced amino acid sequence of the CARM1 protein (SEQ ID NO: 2). The invention also describes isolated CARM1 proteins.

The polypeptides according to the invention can be used in a variety of procedures and methods that are currently applied to other proteins. For example, a polypeptide of the 5 invention can be used to generate an antibody that specifically binds the polypeptide. The invention describes antibodies that specifically interact with the CARM1 protein or fragments thereof.

The polypeptides of the invention also act as methyltransferases of histones and other proteins and can therefore be used for the study of methylation processes in transcription 10 and to methylate amino acid residues within histones and other proteins.

Methylated proteins produced by the methods of the invention can be used to identify demethylating enzymes. Methylated histones, for example, can be used to screen for demethylating enzymes.

The methods of the present invention further relate to the methods for detecting 15 the presence of the polynucleotides or polypeptides of the invention in a sample. Such methods can, for example, be utilized as a prognostic indicator of diseases that involve CARM1, modified forms of CARM1, or altered expression of CARM1.

Methods are also provided for identifying proteins that interact with CARM1 as well as methods for screening of drugs that alter CARM1's interactions with other proteins.

20 Another aspect of the invention is to provide methods to screen for molecules that alter CARM1 methyltransferase activity.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows a comparison of the region of highest homology between CARM1, three other mammalian protein arginine methyltransferases (Lin, W-J. *et al.* 1996; 25 Tang, J. *et al.* (1998) *J. Biol. Chem.* 273:16935; Scott, H.S. *et al.* (1998) *Genomics* 48:330.) and one yeast protein arginine methyltransferase (Gary, J.D. *et al.* 1996); the sequences are shown,

with dashes (-) representing the same amino acid as in CARM1 and dots (.) representing spaces inserted for optimum alignment. The location of a VLD-to-AAA mutation used in these studies is indicated.

Figure 2 shows the expression of CARM1 mRNA in various adult mouse tissues
5 as examined by hybridizing a 0.6-kb BamHI cDNA fragment (representing CARM1 codons 3-198) to a multiple tissue northern blot (Clontech) as described previously (Hong, H. *et al.* 1997). Positions of RNA size markers are shown on the left.

Figure 3 shows the binding *in vitro* of CARM1(SEQ ID NO: 2) and a CARM1 variant (SEQ ID NO: 3) to the C-terminal region of p160 coactivators.

10 Figure 4 shows binding of CARM1 to GRIP1 *in vivo*, i.e. in living yeast. Sub-fragments of the GRIP1 C-terminal domain (GRIP1_c), fused with the Gal4DBD, were tested in the yeast two-hybrid system as described previously (Ding, X.F. *et al.* (1998) *Mol. Endocrinol.* 12:302) for binding to CARM1 or to α -actinin, fused to Gal4AD. β -galactosidase (β -gal) activity indicates interaction between the two hybrid proteins.

15 Figure 5 shows the enhancement by CARM1 of reporter gene activation by Gal4DBD-GRIP1_c. A) CV-1 cells in 6-well dishes (3.3 cm diameter well) were transiently transfected with 0.5 of μ g pM.GRIP1_c (coding for Gal4DBD-GRIP1_c where GRIP1_c is GRIP1 amino acids 1121-1462), 0.5 μ g of GK1 reporter gene (luciferase gene controlled by Gal4 binding sites) (Webb, P. *et al.*, (1998) *Mol. Endocrinol.* 12:1605), and 0 - 0.8 μ g of
20 pSG5.HA-CARM1, using Superfectin (Qiagen) according to manufacturer's protocol. Total DNA was adjusted to 2.0 μ g per well with the appropriate amount of pSG5. Cell extracts were prepared approximately 48 h after transfection and assayed with Promega Luciferase Assay kit. Relative light units of luciferase activity presented are the mean and standard deviation of three transfected wells. B) CV-1 cells were transfected as in A with the indicated amount of
25 pM.GRIP1_c and zero or 0.5 μ g of pSG5.HA-CARM1.

Figure 6 shows the enhancement by CARM1 of reporter gene activation by nuclear receptors and the elimination of CARM1 coactivator function by the VLD-to-AAA

mutation. **(A)** Transient transfection assays with CV-1 cells were performed as in Figure 5 with 0.5 µg of GK1 reporter gene and 0.5 µg of each of the indicated vectors. **(B)** CV-1 cells were transiently transfected as in Figure 5 with the following vectors, as indicated: 0.5 µg of nuclear receptor expression vector pSVAR₀ (Brinkmann, A.O. *et al.* (1989) *J. Steroid Biochem. Molec. Biol.* **34**:307) expressing AR, pHE0 (Green, S. *et al.* (1988) *Nucleic Acids Res.* **16**:369) expressing ER, or pCMX.hTRβ1 (Feng, W. *et al.* (1998) *Science* **280**:1747) expressing TR; 0.5 µg of a luciferase reporter gene with an appropriate promoter, MMTV promoter for AR, or MMTV promoter with the native glucocorticoid response elements replaced by a single estrogen response element for ER or palindromic thyroid hormone response element for TR (Umesono, K. and R.M. Evans (1989) *Cell* **57**:1139); 0.5 µg of pSG5.HA-GRIP1; and 0.5 µg of pSG5.HA-CARM1 or pSG5.HA-CARM1(VLD mutant). Transfection efficiency was monitored by using βgalactosidase activity expressed from 0.1 µg of co-transfected pCMV-βgal vector (Hong, H. *et al.* (1996) *Proc. Natl. Acad. Sci. USA* **93**:4948-4952) as an internal control. After transfection, cells were grown in charcoal-treated serum; where indicated 20 nM hormone (*H*), i.e. dihydrotestosterone for AR, estradiol for ER, or triiodothyronine for TR, was included during the last 40 h of culture. The data is representative of three independent experiments.

Figure 7 shows a model for primary and secondary coactivators of nuclear receptors (NR). Nuclear receptor dimers bind directly to the hormone response element (*HRE*) and activate transcription by recruiting coactivators, which open chromatin structure (signified by *nucleosome*) and recruit a transcription initiation complex (TIC), composed of RNA polymerase II (Pol II), basal transcription factors such as TBP and TFIIB, and a large complex of accessory proteins (Chang, M. and J.A. Jaehning (1997) *Nucleic Acids Res.* **25**:4861). GRIP1 and other p160 family members serve as primary coactivators in this case, binding directly to the NRs. CBP, p/CAF, and CARM1 are recruited by the primary coactivators and thus serve as secondary coactivators. Some coactivators (e.g. CBP) may help to recruit the TIC through direct interactions with basal transcription factors. Some coactivators (e.g. CBP and p/CAF) can acetylate histones, using acetyl-CoA (*AcCoA*). We propose that CARM1's coactivator activity is due to its ability to methylate histones or other proteins in chromatin or the transcription initiation complex, using S-adenosylmethionine (*SAM*) as methyl donor.

Figure 8 shows the histone methyltransferase activity of CARM1. CARM1 and PRMT1 have different protein methyltransferase substrate specificities. CARM1 methylates histone H3, whereas PRMT1 methylates histone H4. PRMT1 was also previously shown to methylate other proteins, including hnRNP A1, but had not previously been shown to methylate histone H4. (A,B) Calf thymus histones (BoehringerMannheim) were incubated for 30 min at 30° C in 32.5 μ l reactions containing 20 mM Tris-Cl, 0.2 M NaCl, 4 mM EDTA, pH 8.0, 0.32 mg/ml individual histone (*2a*, *2b*, *3*, or *4*) or 1.3 mg/ml mixed histone (*M*), 0.037 mg/ml GST-CARM1 or GST-PRMT1, and 7 μ M S-adenosyl-L-[methyl-³H]methionine (specific activity of 14.7 Ci/mmol). Reactions were stopped by addition of SDS-NuPAGE sample buffer (Novex), and 40% of each stopped reaction was then subjected to SDS-PAGE in 4-12% NuPAGE Bis-Tris gradient gels (Novex) using the Na-MES running buffer. Gels were stained with Coomassie Blue R-250 (A), and then subjected to fluorography (Chamberlin, M. (1978) *Anal. Biochem.* 98:132) for 12 h at -70 °C on sensitized Kodak XAR-5 film (B). Molecular weight markers (*MW*) are shown at left. Concentrations of GST fusion proteins were determined in comparison with bovine serum albumin standards (Sigma) by SDS polyacrylamide gel electrophoresis and Coomassie Blue staining; it was assumed that bovine serum albumin stained twice as intensely as most other proteins. Concentrations of histones and hnRNP A1 were determined by the method of Lowry (Lowry, O.H. *et al.* (1951) *J. Biol. Chem.* 193:265). (C) Methylation and electrophoresis were carried out as described above except that protein substrates were 2.7 mg/ml mixed histone (*His*), 0.083 mg/ml hnRNP-A1 (*A1*), or no substrate (-), and the concentrations of GST-CARM1, GST-CARM1 VLD mutant (*VLD*), and GST-PRMT1, were 0.05, 0.02, and 0.03 mg/ml respectively. Two different preparations of the GST-CARM1 VLD mutant failed to show detectable activity towards any substrate. Recombinant human hnRNP A1 expressed in *E. coli* (Mayeda, A. A.R. and Krainer (1995) *Cell* 68:365) was kindly provided by Dr. A. Krainer (Cold Spring Harbor Laboratories, NY).

Figure 9 shows that PRMT1 can also serve as a coactivator for nuclear receptors. Furthermore, CARM1 and PRMT1 act cooperatively as enhancers of nuclear receptor function, i.e. the two together are at least as effective or more effective than the sum of their individual activities. Transient transfections were performed as in Figure 5. CV-1 cells were transfected with the following plasmids: expression vector for nuclear receptor (0.1 μ g pSVAR₀ for

androgen receptor [AR], 0.001 µg of pCMX.TR β 1 for thyroid receptor [TR], or 0.001 µg of pHE0 for estrogen receptor [ER]), 0.25 µg of reporter gene for each nuclear receptor as described in Figure 6B, 0.25 µg of pSG5.HA-GRIP1, and the indicated amount of plasmids encoding CARM1 or PRMT1.

Figure 10 shows that at low levels of nuclear receptor expression, the hormone dependent activity of the nuclear receptors depends almost entirely on the presence of three different coactivators, at least one of which is a protein methyltransferase. Several different combinations of three coactivators work: A) Orphan nuclear receptors ERR3 and ERR1, which require no ligand, are active without exogenously added coactivators when high levels of these nuclear receptors are expressed; but when low levels of these nuclear receptors are expressed (1 ng of expression plasmid in Figure 10A), GRIP1 + CARM1 + PRMT1 is required for activity (226-fold over controls for ERR3 and 13.8-fold over controls for ERR1). Omission of any one of these coactivators almost completely eliminated activity. p160 coactivators other than GRIP1 could be substituted for GRIP1 with similar results. B) When high levels of estrogen receptor are expressed in CV-1 cells (using 100 ng of ER expression vector), the estrogen receptor alone is active, and the activity is enhanced by GRIP1 alone or GRIP1 + one other coactivator (p300 or CARM1) (right side of panel). However, when low levels of estrogen are expressed (using 1-10 ng of ER expression vector) ER alone is almost inactive, and individual coactivators or combinations of any two coactivators cause little stimulation; activity is almost entirely dependent on the presence of GRIP1 + CARM1 + p300 (left side of panel).

Figure 11 shows that PRMT2 and PRMT3 also serve as coactivators for nuclear receptors. CV-1 cells were transiently transfected with expression vectors for the orphan (i.e. no ligand) nuclear receptor ERR3, and where indicated the expression vectors for GRIP1, CARM1, PRMT1, PRMT2, and PRMT3. Like PRMT1 (Figs. 9 & 10), PRMT2 and PRMT3 could enhance nuclear receptor function in cooperation with CARM1.

DETAILED DESCRIPTION

DEFINITIONS

The term "nucleotide sequence" refers to a heteropolymer of nucleotides or the sequence of nucleotides. One of skill in the art will readily discern from contextual cues which 5 of the two definitions is appropriate. The terms "nucleic acid," "nucleic acid molecule" and "polynucleotide" are also used interchangeably herein to refer to a heteropolymer of nucleotides. Generally, nucleic acid segments provided by this invention may be assembled from fragments of the genome and short oligonucleotide linkers, or from a series of oligonucleotides, or from individual nucleotides, to provide a synthetic nucleic acid which is capable of being expressed in 10 a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon, or a eukaryotic gene.

The terms "oligonucleotide fragment" or a "polynucleotide fragment," "portion," or "segment" refer to a stretch of nucleotide residues which is long enough to use in polymerase chain reaction (PCR) or various hybridization procedures to identify or amplify identical or 15 related parts of mRNA or DNA molecules.

"Oligonucleotides" or "nucleic acid probes" are prepared based on the polynucleotide sequences provided herein. Oligonucleotides comprise portions of such a polynucleotide sequence having at least about 15 nucleotides and usually at least about 20 nucleotides. Nucleic acid probes comprise portions of such a polynucleotide sequence having 20 fewer nucleotides than about 3 kb, usually fewer than 1 kb. After appropriate testing to eliminate false positives, these probes may, for example, be used to determine whether specific mRNA molecules are present in a cell or tissue.

The term "probes" includes naturally occurring or recombinant or chemically synthesized single- or double-stranded nucleic acids. They may be labeled by nick translation, 25 Klenow fill-in reaction, PCR or other methods well known in the art. Probes of the present invention, their preparation and/or labeling are elaborated in Sambrook, J. *et al.*, 1989. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York; or Ausubel, F. *et al.*, 1989,

Current Protocols in Molecular Biology, John Wiley & Sons, New York, both of which are incorporated herein by reference in their entirety.

The term “recombinant,” when used herein to refer to a polypeptide or protein, means that a polypeptide or protein is derived from recombinant (e.g., microbial, mammalian, or insect-based) expression systems. “Microbial” refers to recombinant polypeptides or proteins made in bacterial or fungal (e.g., yeast) expression systems. As a product, “recombinant microbial” defines a polypeptide or protein essentially free of native endogenous substances and unaccompanied by associated native glycosylation. Polypeptides or proteins expressed in most bacterial cultures, e.g., *E. coli*, will be free of glycosylation modifications; polypeptides or proteins expressed in yeast may have a glycosylation pattern in general different from those expressed in mammalian cells.

The term “recombinant expression vector” refers to a plasmid or phage or virus or vector, for expressing a polypeptide from a polynucleotide sequence. An expression vector can comprise a transcriptional unit comprising an assembly of: 1) a genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers, 2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and 3) appropriate transcription initiation and termination sequences. It may include an N-terminal methionine residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein to provide a final product.

The term “recombinant expression system” means host cells which have stably integrated a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit extrachromosomally. Recombinant expression systems as defined herein will express heterologous polypeptides or proteins upon induction of the regulatory elements linked to the DNA segment or synthetic gene to be expressed. This term also encompasses host cells which have stably integrated a recombinant genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers. Recombinant expression systems as defined herein will express polypeptides or proteins endogenous to the cell upon induction of the regulatory elements linked to the endogenous DNA segment or gene to be expressed. The cells can be prokaryotic or eukaryotic.

The term “open reading frame,” or “ORF,” means a series of nucleotide triplets coding for amino acids without any termination codons and is a sequence translatable into protein.

- The term “active” refers to those forms of the polypeptide which retain a biologic
- 5 and/or immunologic activity or activities of any naturally occurring polypeptide. An active polypeptide can possess one activity of a polypeptide, but not another, *e.g.*, possess p160 binding activity but lack methyltransferase activity.

The term “naturally occurring polypeptide” refers to polypeptides produced by cells that have not been genetically engineered and specifically contemplates various

10 polypeptides arising from post-translational modifications of the polypeptide including, but not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation.

The term “derivative” refers to polypeptides chemically modified by such techniques as ubiquitination, labeling (*e.g.*, with radionuclides or various enzymes), pegylation (derivatization with polyethylene glycol) and insertion or substitution by chemical synthesis of amino acids such as ornithine, which do not normally occur in human proteins.

- The term “recombinant variant” refers to any polypeptide differing from naturally occurring polypeptides by amino acid insertions, deletions, and substitutions, created using recombinant DNA techniques. Guidance in determining which amino acid residues may be replaced, added or deleted without abolishing activities of interest, such as catalytic activity, may
- 20 be found by comparing the sequence of the particular polypeptide with that of homologous peptides and minimizing the number of amino acid sequence changes made in regions of high homology.

Preferably, amino acid “substitutions” are the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, *i.e.*, conservative

25 amino acid replacements. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids

include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid. “Insertions” or “deletions” are typically in the range of about 1 to 5 amino acids. The variation allowed may be experimentally 5 determined by systematically making insertions, deletions, or substitutions of amino acids in a polypeptide molecule using recombinant DNA techniques and assaying the resulting recombinant variants for activity.

Alternatively, where alteration of function is desired, insertions, deletions or non-conservative alterations can be engineered to produce polypeptide variants. Such variants can, 10 for example, alter one or more of the biological functions or biochemical characteristics of the polypeptides of the invention. For example, such alterations may change polypeptide characteristics such as ligand-binding affinities, interchain affinities, or degradation/turnover rate. Further, such alterations can be selected so as to generate polypeptides that are better suited for expression, scale up and the like in the host cells chosen for expression. For example, cysteine 15 residues can be deleted or substituted with another amino acid residue in order to eliminate disulfide bridges. A variant’s catalytic efficiency can be diminished through deletion or non-conservative substitution of residues important for catalysis.

As used herein, “substantially equivalent” can refer both to nucleotide and amino acid sequences, for example a mutant sequence, that varies from a reference sequence by one or 20 more substitutions, deletions, or additions, the net effect of which does not result in an adverse functional dissimilarity between the reference and subject sequences. Typically, such a substantially equivalent sequence varies from one of those listed herein by no more than about 20% (*i.e.*, the number of individual residue substitutions, additions, and/or deletions in a substantially equivalent sequence, as compared to the corresponding reference sequence, divided 25 by the total number of residues in the substantially equivalent sequence is about 0.20 or less). Such a sequence is said to have 80% sequence identity to the listed sequence. In one embodiment, a substantially equivalent, *e.g.*, mutant, sequence of the invention varies from a listed sequence by no more than 20% (80% sequence identity); in a variation of this embodiment, by no more than 10% (90% sequence identity); and in a further variation of this embodiment, by

no more than 5% (95% sequence identity). Substantially equivalent, *e.g.*, mutant, amino acid sequences according to the invention generally have at least 80% sequence identity with a listed amino acid sequence.

- A polypeptide “fragment,” “portion,” or “segment” is a stretch of amino acid
- 5 residues of at least about 5 amino acids, often at least about 7 amino acids, typically at least about 9 to 13 amino acids, and, in various embodiments, at least about 17 or more amino acids. To be active, any polypeptide must have sufficient length to display biologic and/or immunologic activity.

- Alternatively, recombinant variants encoding these same or similar polypeptides
- 10 may be synthesized or selected by making use of the “redundancy” in the genetic code. Various codon substitutions, such as the silent changes which produce various restriction sites are well known in the art and may be introduced to optimize cloning into a plasmid or viral vector or expression in a particular prokaryotic or eukaryotic system. Mutations in the polynucleotide sequence may be reflected in the polypeptide or domains of other peptides added to the
- 15 polypeptide to modify the properties of any part of the polypeptide, to change characteristics such as ligand-binding affinities, interchain affinities, or degradation/turnover rate.

- The term “purified” as used herein denotes that the indicated nucleic acid or polypeptide is present in the substantial absence of other biological macromolecules, *e.g.*, polynucleotides, proteins, and the like. In one embodiment, the polynucleotide or polypeptide is
- 20 purified such that it constitutes at least 95% by weight, more preferably at least 99.8% by weight, of the indicated biological macromolecules present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 1000 daltons, can be present).

- The term “isolated” as used herein refers to a nucleic acid or polypeptide
- 25 separated from at least one other component (*e.g.*, nucleic acid or polypeptide) present with the nucleic acid or polypeptide in its natural source. In one embodiment, the nucleic acid or polypeptide is found in the presence of (if anything) only a solvent, buffer, ion, or other

component normally present in a solution of the same. The terms “isolated” and “purified” do not encompass nucleic acids or polypeptides present in their natural source.

The term “infection” refers to the introduction of nucleic acids into a suitable host cell by use of a virus or viral vector. The term “transformation” means introducing DNA into a 5 suitable host cell so that the DNA is replicable, either as an extrachromosomal element, or by chromosomal integration. The term “transfection” refers to the taking up of an expression vector by a suitable host cell, whether or not any coding sequences are in fact expressed.

Each of the above terms is meant to encompasses all that is described for each, unless the context dictates otherwise.

10

POLYNUCLEOTIDES AND NUCLEIC ACIDS OF THE INVENTION

The invention provides polynucleotides substantially equivalent to SEQ ID NO: 1, which is the cDNA encoding the polypeptide sequence, SEQ ID NO: 2. The present invention also provides genes corresponding to the cDNA sequences disclosed herein. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic 15 libraries or other sources of genomic materials.

15

The compositions of the present invention include isolated polynucleotides, including recombinant DNA molecules, cloned genes or degenerate variants thereof, especially 20 naturally occurring variants such as allelic variants, novel isolated polypeptides, and antibodies that specifically recognize one or more epitopes present on such polypeptides.

20

The polynucleotides of the invention also include nucleotide sequences that are substantially equivalent to the polynucleotides recited above. Polynucleotides according to the invention can have at least about 80%, more typically at least about 90%, and even more 25 typically at least about 95%, sequence identity to a polynucleotide recited above. The invention also provides the complement of the polynucleotides including a nucleotide sequence that has at least about 80%, more typically at least about 90%, and even more typically at least about 95%, sequence identity to a polynucleotide encoding a polypeptide recited above. The polynucleotide

can be DNA (genomic, cDNA, amplified, or synthetic) or RNA such as mRNA or an antisense RNA. Methods and algorithms for obtaining such polynucleotides are well known to those of skill in the art and can include, for example, methods for determining hybridization conditions which can routinely isolate polynucleotides of the desired sequence identities.

5 A polynucleotide according to the invention can be joined to any of a variety of other nucleotide sequences by well-established recombinant DNA techniques (*see* Sambrook J *et al.* (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY). Useful nucleotide sequences for joining to polypeptides include an assortment of vectors, *e.g.*, plasmids, cosmids, lambda phage derivatives, phagemids, and the like, that are well known in the
10 art. Accordingly, the invention also provides a vector including a polynucleotide of the invention and a host cell containing the polynucleotide. In general, the vector contains an origin of replication functional in at least one organism, convenient restriction endonuclease sites, and a selectable marker for the host cell. Vectors according to the invention include expression vectors, replication vectors, probe generation vectors, and sequencing vectors. A host cell
15 according to the invention can be a prokaryotic or eukaryotic cell and can be a unicellular organism or part of a multicellular organism.

The sequences falling within the scope of the present invention are not limited to the specific sequences herein described, but also include allelic variations thereof. Allelic variations can be routinely determined by comparing the sequence provided in SEQ ID NO: 1, a
20 representative fragment thereof, or a nucleotide sequence at least 98 % identical to SEQ ID NO: 1, with a sequence from another murine isolate. An allelic variation is more typically at least 99% identical to SEQ ID NO: 1 and even more typically 99.8% identical to SEQ ID NO: 1. Furthermore, to accommodate codon variability, the invention includes nucleic acid molecules
25 coding for the same amino acid sequences as do the specific ORFs disclosed herein. In other words, in the coding region of an ORF, substitution of one codon for another which encodes the same amino acid is expressly contemplated. Any specific sequence disclosed herein can be readily screened for errors by resequencing a particular fragment, such as an ORF, in both directions (*i.e.*, sequence both strands).

The present invention further provides recombinant constructs comprising a nucleic acid having the sequence of SEQ ID NO: 1 or a fragment thereof. The recombinant constructs of the present invention comprise a vector, such as a plasmid or viral vector, into which a nucleic acid having the sequence of SEQ ID NO: 1 or a fragment thereof is inserted, in a forward or reverse orientation. In the case of a vector comprising one of the ORFs of the present invention, the vector may further comprise regulatory sequences including, for example, a promoter operably linked to the ORF. Large numbers of suitable vectors and promoters are known to those of skill in the art and are commercially available for generating the recombinant constructs of the present invention.

10 The nucleic acid sequences of the invention are further directed to sequences which encode variants of the described nucleic acids. These amino acid sequence variants may be prepared by methods known in the art by introducing appropriate nucleotide changes into a native or variant polynucleotide. There are two variables in the construction of amino acid sequence variants: the location of the mutation and the nature of the mutation. The amino acid sequence variants of the nucleic acids are preferably constructed by mutating the polynucleotide to give an amino acid sequence that does not occur in nature. In a preferred method, polynucleotides encoding the novel nucleic acids are changed via site-directed mutagenesis.

USE OF NUCLEIC ACIDS AS PROBES

Another aspect of the subject invention is to provide for polypeptide-specific
20 nucleic acid hybridization probes capable of hybridizing with naturally-occurring nucleotide sequences. The hybridization probes of the subject invention may be derived from the nucleotide sequence of SEQ ID NO: 1, fragments or complements thereof. Because the corresponding gene is only expressed in a limited number of tissues, a hybridization probe derived from SEQ ID NO: 1 can be used as an indicator of the presence of RNA of cell type of such a tissue in a sample as
25 shown in Example 1.

Such probes may be of recombinant origin, may be chemically synthesized, or a mixture of both. The probe will comprise a discrete nucleotide sequence for the detection of identical sequences or a degenerate pool of possible sequences for identification of closely

related genomic sequences. Other means for producing specific hybridization probes for nucleic acids include the cloning of nucleic acid sequences into vectors for the production of mRNA probes.

HOSTS

5 The present invention further provides host cells genetically engineered to contain the polynucleotides of the invention. For example, such host cells may contain nucleic acids of the invention introduced into the host cell using known transformation, transfection or infection methods. The present invention still further provides host cells genetically engineered to express the polynucleotides of the invention, wherein such polynucleotides are in operative association
10 with a regulatory sequence heterologous to the host cell which drives expression of the polynucleotides in the cell.

The host cell can be a higher eukaryotic host cell, such as a mammalian cell or an insect cell, a lower eukaryotic host cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the recombinant construct into the host cell can be effected by calcium phosphate transfection, DEAE, dextran mediated transfection, or electroporation (Davis, L. *et al.*, *Basic Methods in Molecular Biology* (1986)). The host cells containing one of polynucleotides of the invention, can be used in conventional manners to produce the gene product encoded by the isolated fragment (in the case of an ORF) or can be used to produce a heterologous protein under the control of an appropriate promoter region.

20 Any host/vector system can be used to express one or more of the ORFs of the present invention. These include, but are not limited to, eukaryotic hosts such as HeLa cells, CV-1 cell, COS cells, and Sf9 cells, as well as prokaryotic host such as *E. coli* and *B. subtilis*. The most preferred cells are those which do not normally express the particular polypeptide or protein or which expresses the polypeptide or protein at low natural level. Mature proteins can
25 be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, *et*

al., in Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, New York (1989).

REGULATION OF TRANSCRIPTION

Polynucleotides of the invention and vectors capable of expressing these
5 polynucleotides are useful for the regulation of transcription in cells.

Increased expression of CARM1 in cells enhances the function of nuclear receptor coactivators of the p160 family including GRIP1, SRC-1, and p/CIP. CARM1 expression in mammalian cells enhances the activity of full length GRIP1 or of the C-terminal domain of GRIP1 attached to the DNA binding domain of a heterologous protein. Increased expression of
10 CARM1 in cells, in conjunction with increased expression of coactivators of the GRIP1 family, enhances the function of nuclear receptors. The enhancement by CARM1 is over and above that achieved by the increased expression of a GRIP1-type coactivator. Thus, CARM1 can serve as a coactivator for nuclear receptors.

The activity of other transcriptional activator proteins that rely on GRIP1-type
15 coactivators will be enhanced by increased expression of CARM1. Examples of other transcriptional activator proteins that may use GRIP1-type coactivators are other nuclear receptors, AP1, and STATs (Glass CK *et al.* (1997) *Curr. Opin. Cell Biol.* 9:222-232; Kamei Y *et al.* (1996) *Cell* 85:403-414; Korzus E *et al.* (1998) *Science* 279:703-707; Yao T-P *et al.* (1996) *Proc. Natl. Acad. Sci. USA* 93:10626-10631).

20 CARM1 polynucleotides or polypeptides can also be used in conjunction with other transcriptional activating molecules to increase transcription of a nuclear receptor-dependent gene. In one embodiment, CARM1 is expressed simultaneously with a histone acetyltransferase (HAT). Transcription of a gene under the control of a nuclear receptor is synergistically enhanced by the presence of CARM1 and a HAT.

GENE THERAPY

Polynucleotides of the present invention can also be used for gene therapy for the treatment of disorders which are mediated by CARM1, certain hormones, such as those that act as ligands for nuclear hormone receptors, or by nuclear hormone receptors. Such therapy 5 achieves its therapeutic effect by introduction of the appropriate CARM1 polynucleotide (*e.g.*, SEQ ID NO: 1) which contains a CARM1 gene (sense or antisense), into cells of subjects having the disorder to increase or decrease CARM1 activity in the subjects' cells. Delivery of sense or antisense CARM1 polynucleotide constructs can be achieved using a recombinant expression vector such as a chimeric virus or a colloidal dispersion system. An expression vector including 10 the CARM1 polynucleotide sequence may be introduced to the subject's cells *ex vivo* after removing, for example, stem cells from a subject's bone marrow. The cells are then reintroduced into the subject, (*e.g.*, into subject's bone marrow).

Various viral vectors which can be utilized for gene therapy as taught herein include adenovirus, herpes virus, vaccinia, or, preferably, an RNA virus such as a retrovirus. 15 Preferably, the retroviral vector is a derivative of a murine or avian retrovirus. Examples of retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), Rous Sarcoma Virus (RSV), and gibbon ape leukemia virus (GaLV), which provides a broader host range than many of the murine viruses. A number of 20 additional retroviral vectors can incorporate multiple genes. All of these vectors can transfer or incorporate a gene for a selectable marker so that transduced cells can be identified and selected for. By inserting a CARM1 sequence of interest into the viral vector, along with another gene which encodes the ligand for a receptor on a specific target cell, for example, the vector is now target specific. Preferred targeting is accomplished by using an antibody to target the retroviral 25 vector. Those of skill in the art will know of, or can readily ascertain without undue experimentation, specific polynucleotide sequences which can be inserted into the retroviral genome to target a specific retroviral vector containing the CARM1 sense or antisense polynucleotide.

Since recombinant retroviral vectors usually are defective, they require assistance to produce infectious vector particles. This assistance can be provided, for example, by using helper cell lines that contain plasmids encoding all of the structural genes of the retrovirus under the control of regulatory sequences within the LTR. These plasmids are missing a nucleotide sequence which enables the packaging mechanism to recognize an RNA transcript for encapsidation. Helper cell lines which have deletions of the packaging signal include but are not limited to PSL2, PA317 and PA12, for example. These cell lines produce empty virions, since no genome is packaged. If a retroviral vector in which the packaging signal is intact, but the structural genes are replaced by other genes of interest is introduced into such cells, the vector will be packaged and vector virions produced.

Since CARM1 promotes the action of nuclear receptors, CARM1 or vectors expressing CARM1 may be useful as agonists to stimulate processes mediated by nuclear receptors. For example, glucocorticoids are used as anti-inflammatory agents. Gene therapy applications of CARM1 may enhance the anti-inflammatory effects of glucocorticoids and could thus enhance the glucocorticoids' therapeutic effectiveness or reduce the concentration of glucocorticoids required to provide the desired anti-inflammatory effects.

The CARM1 nucleotide and predicted amino acid sequence, combined with the functional domains of CARM1, can be used to design modified forms of CARM1 that lack the methyltransferase activity but retain the ability to bind GRIP1-type coactivators. For example, we have shown that mutations in the region of CARM1 that contains the methyltransferase activity produce such a modified CARM1 protein. Also, a fragment of CARM1 protein that contains the GRIP1-binding function but lacks the methyltransferase region will also have the same properties. Such forms of CARM1 have a "dominant negative" effect on nuclear receptor function; *i.e.*, when expressed in cells, these dominant negative forms of CARM1 reduce the activity of nuclear receptors. This approach is effective in cells that naturally express CARM1 or a functionally equivalent protein from the native endogenous gene. The dominant negative variant of CARM1 interferes with the function of the endogenous CARM1 (or functionally equivalent protein) as follows: When nuclear receptors bind to a target gene, they recruit a GRIP1-type coactivator, which would normally recruit CARM1. However, if the dominant

negative form of CARM1 is expressed in higher levels than the endogenous intact CARM1, then the dominant negative CARM1 is more likely to bind to GRIP1 instead of the endogenous active CARM1. The recruited dominant negative form of CARM1 fails to activate gene expression (since it has no methyltransferase), and also blocks the endogenous intact CARM1 protein from binding to GRIP1 and carrying out its function. Thus, the expression of the dominant negative CARM1 reduces the nuclear receptor's ability to activate gene expression by interfering with the function of endogenous CARM1. The same forms of CARM1 should have a dominant negative effect on any transcription factor whose function is normally enhanced by intact CARM1. We have demonstrated that a CARM1 mutant (CARM1 VLD mutant), in which the amino acids valine189, leucine190, and aspartic acid191 (V189A/L190A/D191A) have all been changed to alanine, lacks methyltransferase activity, lacks coactivator activity, and inhibits nuclear receptor function in conditions where GRIP1-type coactivators are limiting.

Examples of specific uses for such antagonistic reagents are in the treatment of breast cancer and prostate cancer. Most breast cancers, at least initially, rely on estrogen for growth; and most prostate cancers, at least initially, depend on androgens for growth. Since CARM1 promotes estrogen and androgen receptor action, antagonists of CARM1 or other methyltransferases may block or partially block the growth promoting effects of the hormones estrogen and androgen on these tumors. These antagonists may serve as effective chemotherapeutic agents, either when used alone or when used in combination with other types of treatments.

POLYPEPTIDES OF THE INVENTION

The isolated polypeptides of the invention include, but are not limited to, a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or fragments thereof.

The invention also relates to methods for producing a polypeptide comprising growing a culture of the cells of the invention in a suitable culture medium, and purifying the protein from the culture. For example, the methods of the invention include a process for producing a polypeptide in which a host cell containing a suitable expression vector that includes a polynucleotide of the invention is cultured under conditions that allow expression of the

encoded polypeptide. The polypeptide can be recovered from the culture, conveniently from the culture medium, and further purified. Preferred embodiments include those in which the protein produced by such process is a full length or mature form of the protein.

The invention also provides a polypeptide including an amino acid sequence that
5 is substantially equivalent to SEQ ID NO: 2. Polypeptides according to the invention can have at least about 80%, and more typically at least about 90%, and even more typically 95% sequence identity to SEQ ID NO: 2.

The present invention further provides isolated polypeptides encoded by the nucleic acid fragments of the present invention or by degenerate variants of the nucleic acid
10 fragments of the present invention. By “degenerate variant” is intended nucleotide fragments which differ from a nucleic acid fragment of the present invention (e.g., an ORF) by nucleotide sequence but, due to the degeneracy of the genetic code, encode an identical polypeptide sequence. Preferred nucleic acid fragments of the present invention are the ORFs that encode proteins.

Methodologies known in the art can be utilized to obtain any one of the isolated polypeptides or proteins of the present invention. At the simplest level, the amino acid sequence can be synthesized using commercially available peptide synthesizers. This is particularly useful in producing small peptides and fragments of larger polypeptides. Fragments are useful, for example, in generating antibodies against the native polypeptide. In an alternative method, the
15 polypeptide or protein is purified from cells which naturally produce the polypeptide or protein. One skilled in the art can readily follow known methods for isolating polypeptides and proteins to obtain one of the isolated polypeptides or proteins of the present invention. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography, and immuno-affinity chromatography. See, e.g., Scopes, Protein Purification: Principles and Practice, Springer-Verlag (1994); Sambrook, *et al.*, in Molecular Cloning: A Laboratory Manual (*supra*); Ausubel *et al.*, Current Protocols in Molecular Biology (*supra*).

The polypeptides and proteins of the present invention can alternatively be purified from cells which have been altered to express the desired polypeptide or protein. One skilled in the art can readily adapt procedures for introducing and expressing either recombinant or synthetic sequences into eukaryotic or prokaryotic cells in order to generate a cell which 5 produces one of the polypeptides or proteins of the present invention. The purified polypeptides can be used in *in vitro* binding assays which are well known in the art to identify molecules which bind to the polypeptides.

The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to 10 those skilled in the art. For polypeptides more than about 100 amino acid residues, a number of smaller peptides will be chemically synthesized and ligated either chemically or enzymatically to provide the desired full-length polypeptide. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with naturally occurring proteins may possess biological properties in common therewith. Thus, 15 they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The proteins provided herein also include proteins characterized by amino acid sequences substantially equivalent to those of purified proteins but into which modification are 20 naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the 25 conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Pat. No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.

Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are intended to be encompassed by the present invention.

5 The protein of the invention may also be expressed in a form that will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, Mass.), Pharmacia (Piscataway, N.J.) and Invitrogen (Carlsbad, CA),
10 respectively. The protein also can be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from Kodak (New Haven, Conn.).

15 Our knowledge of CARM1 should make it possible to design and screen drugs that block the methyltransferase activity of CARM1. The CARM1 protein can in principle be used for X-ray crystallographic, or other structural studies, to determine the 3 dimensional structure of the active site (including the binding sites for S-adenosylmethionine and the protein substrate which accepts methyl groups) of the methyltransferase region of CARM1. Once determined, this structure can be used for rational drug design, to design drugs to block the substrate binding and activate sites of CARM1. These or randomly selected candidates can be
20 screened using the methyltransferase activity assays we have developed.

There are other protein arginine methyltransferases related to CARM1 (Lin, W-J. *et al.* 1996; Gary, J.D. *et al.* 1996; Aletta, J.M. *et al.* 1998), and there may be others which are unknown at this time. Some of these other protein arginine methyltransferases and possibly even some other types of protein methyltransferases (*e.g.*, lysine methyltransferases and carboxyl
25 methyltransferases (Aletta, J.M. *et al.* 1998) may also be involved in gene regulation by a mechanism similar to that of CARM1. Our knowledge of the CARM1 sequence and mechanism provides the tools to search for related genes and proteins and the knowledge to determine whether any of these other methyltransferases are involved in regulation of transcription.

ANTIBODIES

Another aspect of the invention is an antibody that specifically binds the polypeptide of the invention. Such antibodies can be either monoclonal or polyclonal antibodies, as well as fragments thereof and humanized forms or fully human forms, such as those produced
5 in transgenic animals. The invention further provides a hybridoma that produces an antibody according to the invention. Antibodies of the invention are useful for detection and/or purification of the polypeptides of the invention.

Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies that react specifically with the protein. Such antibodies
10 may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the amino or carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R. P. Merrifield, *J. Amer. Chem. Soc.* **85**, 2149-2154 (1963); J. L. Krstenansky, *et al.*, *FEBS Lett.* **211**, 10 (1987).

15 Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for conditions associated with excess production or accumulation of the protein. In general, techniques for preparing polyclonal and monoclonal antibodies as well as hybridomas capable of producing the desired antibody are well known in
20 the art (Campbell, A.M., Monoclonal Antibodies Technology: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam, The Netherlands (1984); St. Groth *et al.*, *J. Immunol.* **35**:1-21 (1990); Kohler and Milstein, *Nature* **256**:495-497 (1975)). Other useful techniques include the trioma technique and the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* **4**:72 (1983); Cole *et al.*, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985), pp. 77-96).

Any animal (rabbit, etc.) which is known to produce antibodies can be immunized with a peptide or polypeptide of the invention. Methods for immunization are well known in the art. Such methods include subcutaneous or intraperitoneal injection of the polypeptide. One skilled in the art will recognize that the amount of the protein encoded by the ORF of the present

invention used for immunization will vary based on the animal which is immunized, the antigenicity of the peptide and the site of injection. The protein that is used as an immunogen may be modified or administered with an adjuvant to increase the protein's antigenicity. Methods of increasing the antigenicity of a protein are well known in the art and include, but are 5 not limited to, coupling the antigen with a heterologous protein (such as globulin or β -galactosidase) or through the inclusion of an adjuvant during immunization.

For monoclonal antibodies, spleen cells from the immunized animals are removed, fused with myeloma cells, such as SP2/0-Ag14 myeloma cells, and allowed to become monoclonal antibody producing hybridoma cells. Any one of a number of methods well known 10 in the art can be used to identify the hybridoma cell which produces an antibody with the desired characteristics. These include screening the hybridomas with an ELISA assay, western blot analysis, or radioimmunoassay (Lutz *et al.*, *Exp. Cell Research*, 175:109-124 (1988)).

Hybridomas secreting the desired antibodies are cloned and the class and subclass is determined using procedures known in the art (Campbell, A.M., Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science 15 Publishers, Amsterdam, The Netherlands (1984)). Techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce single chain antibodies to proteins of the present invention.

For polyclonal antibodies, antibody containing antiserum is isolated from the 20 immunized animal and is screened for the presence of antibodies with the desired specificity using one of the above-described procedures. The present invention further provides the above-described antibodies in detectably labeled form. Antibodies can be detectably labeled through the use of radioisotopes, affinity labels (such as biotin, avidin, *etc.*), enzymatic labels (such as horseradish peroxidase, alkaline phosphatase, *etc.*) fluorescent labels (such as FITC or 25 rhodamine, *etc.*), paramagnetic atoms, *etc.* Procedures for accomplishing such labeling are well-known in the art, for example, see Sternberger, L.A. *et al.*, *J. Histochem. Cytochem.* 18:315 (1970); Bayer, E.A. *et al.*, *Meth. Enzym.* 62:308 (1979); Engval, E. *et al.*, *Immunol.* 109:129 (1972); Goding, J.W. *J. Immunol. Meth.* 13:215 (1976).

In diagnostic uses, it is possible that some medical conditions may derive from abnormal forms or levels of expression of CARM1 or other methyltransferases. Thus, nucleic acid and antibody reagents derived from CARM1 or other methyltransferases may be used to screen humans for such abnormalities. Similarly, there may be different alleles of CARM1 or 5 other methyltransferases that predispose carriers to be more susceptible to specific drugs or diseases. The CARM1 reagents can be used to define such allelic variations and subsequently to screen for them.

Antibodies of the invention can also be generated that specifically recognize substrates that have been methylated by CARM1. For example, CARM1 methylates residues 10 arg2, arg17 and arg26 of histone H3. Antibodies to peptides containing methylated arginines at these, or other positions of CARM1 methylation, are useful for studying the role of methylation in gene expression.

METHYLTRANSFERASE ACTIVITY

CARM1 can transfer one or more methyl groups from S-adenosylmethionine to an 15 arginine residue in proteins and in synthetic peptides. Appropriate substrate proteins include histones. CARM1 can transfer methyl groups from S-adenosylmethionine to one or more arginine residues in histone H3, producing monomethyl and asymmetrically dimethylated N^G,N^G-dimethylarginine residues in histone H3. The CARM1 VLD (SEQ ID NO:3) mutant lacks 20 methyltransferase activity for both histone H3 and the synthetic peptide substrates and lacks coactivator activity.

SUBSTRATES OF CARM1

While the identity of additional proteins (other than histone H3) that CARM1 methylates remains unknown, we have established a procedure for identifying proteins that are methylated by CARM1, by incubating candidate substrate proteins or protein fractions or extracts 25 with recombinant CARM1 and S-adenosylmethionine and then analyzing the products by chromatography or electrophoresis. The purified protein can be sequenced to learn its identity. The yeast two hybrid system, used to discover CARM1, also should be useful for defining proteins that bind to CARM1 methyltransferase and thus are possible substrates. Once

identified, these methylation substrates of CARM1 should be useful as reagents for studying the role and mechanism of methylation in gene regulation. They also serve as additional sites of intervention for blocking or enhancing gene expression. This is accomplished by increasing the expression of the protein substrate or by reducing expression of the protein substrate, for example

5 by using antisense techniques or by expressing altered forms of the protein substrate which have a dominant negative effect and thus block the function of the endogenous native protein substrate.

Because protein methylation is involved in regulation of gene transcription, a mechanism for demethylation of the same proteins likely exists. Histone H3 is a substrate for

10 CARM1, and we have described methods for identifying other protein substrates of CARM1 above. These methylated proteins can serve as the basis for identifying demethylating enzymes. In such a method, a methylated protein preparation is incubated with cell extracts, fractions of cell extracts or with candidate proteins. Demethylation can be monitored by release of radioactivity if the methylated protein is prepared with radioactively labeled S-adenosyl-methionine. Demethylation can also be monitored by chromatographic changes, using techniques such as ion-exchange chromatography; by mass spectrometry; by spectroscopic techniques such as fluorescence spectropscopy; or by immunoassays with antibodies raised against the methylated or non-methylated forms of the protein. Once identified, these demethylating enzymes can be used as the basis for developing reagents to enhance or block

15

20 demethylation. Blocking or enhancing demethylation should have the opposite effect from blocking or enhancing methylation by CARM1.

SCREENING OF CARM1 INHIBITORS

Inhibitors of CARM1 can be discovered using the methods of the invention that act through a variety of mechanisms. In one embodiment, molecules are screened for their ability

25 to inhibit CARM1 methyltransferase activity. Methyltransferase activity can be determined using any of the assays described herein, or other suitable biochemical assays. For example, in one embodiment a substrate protein, such as histone H3 is incubated with a candidate inhibitor molecule or pool of molecules along with CARM1 (SEQ ID NO: 2) and radioactively labeled S-adenosylmethionine. The degree of radioactive labeling of the target histone is measured by

separating the labeled protein from the free S-adenosylmethionine. Separation may be effected by chromatography or by using a low molecular weight cut-off membrane, through which the free S-adenosylmethionine passes, but the labeled protein is retarded. The activity of CARM1 is then compared in the presence and absence of the candidate inhibitor.

5 CARM1 inhibitors can also be discovered that prevent interaction of CARM1 with a coactivator such as GRIP1. The disclosed two-hybrid assays for measuring the binding interaction between coactivators and CARM1 are also suitable for use as a screening system to identify compounds that can block binding of CARM1 to GRIP1-type coactivators.

10 In one embodiment, CARM1 (SEQ ID NO: 1) or a fragment thereof, is expressed in a host cell as a fusion with either a DNA binding domain (DBD) or with a transcriptional activation domain (AD). DNA binding domains are well known in the art, and can be chosen from any DNA binding protein or transcription factor. In one embodiment, CARM1 is expressed fused with the DNA binding domain of Gal4. In another embodiment, CARM1 is expressed instead fused to a transcriptional activation domain from Gal4.

15 A GRIP1-type coactivator, or a fragment thereof, is expressed as a fusion with either a DNA binding domain or with a transcriptional activation domain, but not with the domain type chosen for CARM1. If CARM1 is fused with a DNA binding domain, then the GRIP1-type coactivator domain must be fused with a transcriptional activating domain.

20 In such a method, a reporter gene construct is also provided. The reporter gene construct comprises a reporter gene and a promoter region. Reporter genes encode a protein that can be directly observed or can be indirectly observed through an enzymatic activity or through immunogenic detection methods. Directly observable proteins can be fluorescent proteins, such as the green fluorescent protein (GFP) of *Aequorea*. Indirectly observable proteins commonly possess an enzymatic activity capable of affecting a chromogenic or fluorogenic change in a 25 specific substrate. Such proteins include β -lactamase, luciferase and β -galactosidase. Reporter gene expression can also be monitored with antibodies directed towards the gene product, or by measuring the RNA levels produced.

In the two hybrid system, the interaction of CARM1-AD hybrid protein with the GRIP1-DBD hybrid protein leads to the expression of the reporter gene, and thus, the expression of the reporter gene serves as an indication that CARM1 and GRIP1 can bind to each other.

Upon consideration of the present disclosure, one of skill in the art will appreciate
5 that many other embodiments and variations may be made in the scope of the present invention.
Accordingly, it is intended that the broader aspects of the present invention not be limited to the
disclosure of the following examples, but rather only to the scope of the appended claims.

EXAMPLE 1

Isolation of murine CARM1 cDNA

10 A 3.2-kb partial CARM1 cDNA clone with an open reading frame of 606 amino acids (CARM1(3-608)), followed by a 1.4 kb 3'-untranslated region and a poly A sequence, was isolated from a mouse 17-day embryo library by using the yeast two-hybrid system as described previously (Hong, H. *et al.* 1996). The EcoRI library (Clontech) was in vector pGAD 10 which has a *leu2* marker gene; the bait was GRIP1_c (GRIP (1122-1462)) in vector pGBT9 (Clontech)
15 which has a *trp1* marker gene. Further screening of a lambda phage library of mouse 11-day embryo cDNA clones (Stratagene) identified additional 5'-sequences and allowed construction of a putative full length coding region for CARM1 (608 amino acids). Amino acids 143-457 of CARM1 share 30% identity with hPRMT1 and yODP1. A clone coding for a C-terminal fragment of α -actinin was isolated in the same yeast two hybrid screen with pGBT9.GRIP1_c.

20 A BLAST search of the GenBank database (Altschul, S.F. *et al.* (1990) *J. Mol. Biol.* **215**:403-410) indicated that this coding region represents a novel protein, whose central region shares extensive homology with a family of proteins with arginine-specific protein methyltransferase activity (Figure 1). We therefore named the new protein Coactivator Associated arginine (R) Methyltransferase 1 (CARM1). RNA blot analysis indicated that the
25 CARM1 cDNA represents a 3.8-kb mRNA which is expressed widely, but not evenly, in adult mouse tissues including in heart, brain, liver, kidney, and testis; testis also contains a homologous 4.1-kb RNA species (Figure 2). Lower expression was observed in spleen, lung, and skeletal muscle. Northern blot analysis was performed as shown in Figure 2 with a 0.6-kb

BamHI cDNA fragment (representing CARM1 codons 3-198) and with RNA from multiple tissues as described previously (Hong *et al.* 1997).

EXAMPLE 2

Construction of Plasmids

- 5 Mammalian cell expression vector: pSG5.HA was constructed by inserting a synthetic sequence coding for a translation start signal, HA tag, EcoRI site, and XhoI site into the EcoRI-BamHI site of pSG5 (Stratagene), which has SV40 and T7 promoters. The original EcoRI site is destroyed by this insertion, but the BamHI site is preserved, leaving a multiple cloning site after the HA tag containing EcoRI, XhoI, BamHI, and BglII sites. The following protein coding
10 regions were cloned into pSG5.HA, in frame with the HA tag, using the indicated insertion sites: GRIP1 (5-1462) (full length) and CARM1 (3-608) (full length) at the EcoRI site; GRIP1 (5-765) at the EcoRI-XhoI site; GRIP1 (730-1121) and GRIP1 (1121-1462) were EcoRI-SalI fragments inserted at the EcoRI-XhoI site; SRC-1a (1-1441) (full length) was a SmaI-SalI fragment inserted at the EcoRI site, which was blunted by filling with Klenow polymerase, and the XhoI site.
15 Expression vector for Gal4DBD-GRIP1_c was constructed by inserting an EcoRI-BglII fragment coding for GRIP1 (1122-1462) into pM (Clontech). Vectors for GST fusion proteins were constructed in pGEX-4T1 (Pharmacia): for GST-CARM1 the original 3.2-kb EcoRI fragment from pGAD10.CARM1 was inserted; for GST-GRIP1c (amino acids 1122-1462) a EcoRI-SalI fragment was inserted. Yeast expression vectors for Gal4DBD fused to various GRIP1
20 fragments were constructed by inserting EcoRI-SalI fragments into pGBT9. The GRIP1_cΔ19 and CARM1 VLD mutations were engineered with the Promega Gene Editor Kit. Constructions of all the above plasmids was described previously (Chen, D. *et al.* (1999) *Science* 284:2174-2177).

EXAMPLE 3

Binding interactions of CARM1.

- 25 This example demonstrates that CARM1 interacts with GRIP1. The binding of GRIP1_c to CARM1 observed in the yeast two-hybrid system was confirmed *in vitro*, by incubating glutathione S-transferase (GST) fusion proteins attached to glutathione agarose beads with labeled proteins or protein fragments translated *in vitro*. GST-CARM1 bound GRIP1_c

(amino acids 1122-1462) but not protein fragments representing GRIP1 amino acids 5-765 or 730-1121 (Figure 3A). Conversely, GST-GRIP1_c bound CARM1 and the VLD to AAA mutant of CARM1 (Figure 3B). GST-CARM1 not only bound GRIP1 but also the other two members of the p160 coactivator family, SRC-1a and ACTR (Figure 3A). Thus, Figure 3 shows the
5 binding of CARM1 to the C-terminal region of p160 coactivators. GST fusion proteins of CARM1 or the indicated GRIP1 fragments produced in *E. coli* strain BL21 (Stratagene), were bound to glutathione-agarose beads and incubated with labeled full length CARM1 or p160 coactivators or GRIP1 fragments translated *in vitro* from vector pSG5.HA-CARM1,
10 pSG5.HA-GRIP1, pSG5.HA-SRC-1a (Chen, D. *et al.* 1999), or pCMX.ACTR (Chen *et al.* 1997); bound labeled proteins were eluted and analyzed by SDS polyacrylamide gel electrophoresis as described previously (Hong *et al.* 1996). A mutant form of CARM1 with the triple amino acid substitution (VLD changed to AAA) shown in Figure 1 still retains the ability to bind to the C-terminal fragment of GRIP1.
15

The binding site for CARM1 in GRIP1_c was further mapped by using the yeast
two hybrid system. When GRIP1_c was bisected between amino acids 1210 and 1211, the
N-terminal fragment fails to bind CARM1, while the C-terminal fragment retains binding
activity; thus GRIP 1211-1462 is sufficient for CARM1 binding while amino acids 1121-1210
are neither necessary nor sufficient (Figure 4). When GRIP1_c was bisected between amino acids
1305 and 1306, neither fragment bound CARM1, indicating that sequences near this boundary
20 were important for CARM1 binding. This conclusion was supported by the finding that deletion
of amino acids 1291-1309 (GRIP1_cΔ19 mutant), which are highly conserved among p160
proteins (Anzick, S.L. *et al.* 1997), eliminate CARM1 binding. The smallest GRIP1 fragment
that binds to CARM1 is the fragment from 1211-1350. Controls with α-actinin, another protein
found to bind GRIP1_c in the yeast two hybrid screen, had a different pattern of binding to the
25 GRIP1 fragments and provided positive and negative controls. We conclude that CARM1 binds
to the C-terminal region of GRIP1 defined by amino acids 1211-1350 and that a highly conserved
stretch of 19 amino acids (1291-1309) is important for CARM1 binding.

EXAMPLE 4

Enhancement of GRIP1 and NR function by secondary coactivator CARM1.

This example demonstrates that CARM1 expression in mammalian cells enhances the transcriptional activation activity of GRIP1_c fused to the DBD of Gal4 protein. In transient transfections of CV-1 cells, Gal4DBD-GRIP1_c weakly activates expression of a reporter gene with a promoter containing Gal4 binding sites; co-expression of CARM1 enhances reporter gene activity in a dose-dependent manner and provides a maximum stimulation of more than 10-fold (Figure 5). CARM1 expression has little if any effect on the activity of Gal4DBD alone (Figure 6A). CARM1 also enhances the activity of full length GRIP1 fused to Gal4DBD.

CARM1 also enhances GRIP1's coactivator function for nuclear receptors (NR). When the androgen receptor, estrogen receptor, and thyroid hormone receptor are expressed in CV-1 cells by transient transfection, their abilities to activate transcription of a reporter gene carrying appropriate hormone response elements in the promoter are hormone dependent (Figure 6B, lanes a & b). Co-expression of GRIP1 from a co-transfected plasmid causes a 2 to 27-fold enhancement of reporter gene expression by the hormone-activated NR (lane d). These activities are enhanced 2 to 4-fold more by co-expression of CARM1 with the NR and GRIP1 (lane e). However, in the absence of exogenous GRIP 1, CARM1 has little or no effect on the activity of the NR (lane c). Co-expression of NR, GRIP1, and CARM1 in the absence of hormone produces extremely low reporter gene activities equivalent to those seen with NR alone in the absence of hormone (lane f). A similar enhancement of NR function by CARM1 is observed when SRC-1a or ACTR (two other GRIP1 related coactivators) is substituted for GRIP1 in a similar experiment. The fact that CARM1's ability to enhance NR activity depends on co-expression of exogenous GRIP1 is consistent with a model whereby CARM1 interacts with NRs indirectly, through a p160 coactivator, rather than directly (Figure 7). It also suggests that in the transient transfection assays, the expression of exogenous NRs renders the levels of endogenous p160 coactivators limiting, so that the effects of exogenous CARM1 expression can only be observed when additional p160 coactivators are also expressed. We conclude that CARM1 acts as a secondary coactivator for NRs by binding to and mediating or enhancing the activity of the p160 primary coactivators.

EXAMPLE 5

Histone methyltransferase activity of CARM1

This example shows that CARM1 is a protein arginine methyltransferase. The homology between CARM1 and arginine-specific protein methyltransferases includes sequences
5 that are highly conserved throughout the family and are believed to be important for methyltransferase activity (Figure 1). We compared the methyltransferase activities of GST fusion proteins of CARM1 and a related mammalian enzyme, Protein arginine (R) MethylTransferase 1 (PRMT1) (Lin, W-J. *et al.* 1996), for various substrates, using S-adenosylmethionine labeled in the donor methyl group. Mixed histones are good substrates for
10 both enzymes (Figure 8). Gel electrophoresis and autoradiography of the methylated histone products, and tests with purified individual histone species, indicate that CARM1 methylates histones H3 and H2a, while PRMT1 methylates histones H4 and H2a (Figure 8B). Both enzymes methylate histone 2a in the absence of other histones but not in the histone mixture, suggesting that hetero-oligomerization of the histones may render histone 2a inaccessible to
15 methylation (Figure 8B). The positions of the small amounts of labeled products in the histone H2b lanes for CARM1 and PRMT1 suggest that these products are minor amounts of H3 and H4 contaminating the H2b preparation. The specific activities of CARM1 and PRMT1 with the mixed histone substrate are very similar (Table 1). Our result for PRMT1 is different from one in a previous report (Gary and Clarke 1998), that PRMT1 methylates histone H2b but none of the
20 other core histones. RNA binding protein hnRNPA1 is a good substrate for PRMT1, as shown previously (Lin W-J, *et al.* 1996), but is not methylated by CARM1 (Figure 8C). Both enzymes methylate the glycine-rich R1 peptide substrate (SEQ ID NO: 4: GGFGRGGFG-NH₂), which was previously shown to be a good substrate for PRMT1 and other protein arginine methyltransferases (Lin, W-J. *et al.* 1996; Najbauer, J. *et al.* 1993). However, this peptide is a
25 relatively poor substrate for CARM1; the specific activity of GST-PRMT1 for the R1 peptide is approximately 100 times higher than that of GST-CARM1 (Table 1). CARM1 fails to methylate the same peptide with lysine substituted for the arginine residue, demonstrating its specificity for arginine.

Table 1. Relative methyltransferase activities of GST-CARM1 and GST-PRMT1.

Methyltransferase reactions (50 µl) were carried out as described in Figure 8 at enzyme concentrations of 0.03-0.05 mg/ml. Reactions were stopped by addition of 25 µl of 1.5% (v/v) trifluoroacetic acid (TFA), 15% (v/v) acetonitrile in water and subjected to reversed-phase HPLC 5 as described (Najbauer *et al.* 1993) to separate the substrate from unreacted S-adenosylmethionine. For the histone methylation, TFA in the HPLC solvents was increased to 0.3% (v/v) and the gradient was modified to accommodate the more retentive behavior of the histones.

Substrate	Methyltransferase specific activity (pmol/min/mg)	
	GST-CARM1	GST-PRMT1
R1 peptide (120 µM) SEQ ID NO: 4 GGF G GRGGFG-NH ₂	21.6-54.5 ^a	3,070
K1 peptide (120 µM) SEQ ID NO: 5 GGF G GKGGFG-NH ₂	0.7	not determined
mixed histones (2.7 mg/ml) (calf thymus)	971	1,180

^aResult of two separate determinations using different preparations of GST-

10 CARM1.

EXAMPLE 6

Identification of the methylated amino acids produced in histone H3 by CARM1

Histone H3 was incubated for 60 min at 30°C in a 100 µl methylation reaction as described in Figure 8, containing 0.024 mg/ml GST-CARM1 and 0.63 mg/ml H3. The reaction 15 was stopped with 25 µl of 3% (v/v) trifluoroacetic acid (TFA), 15% (v/v) acetonitrile, and 100 µl was injected into a 3 cm x 4.6 mm RP-300 reversed-phase guard column (Perkin Elmer-Brownlee) equilibrated with 80% solvent A (0.3% TFA in water) and 20% solvent B (0.3% TFA in acetonitrile). Methylated H3 was separated from unreacted S-adenosylmethionine

using a gradient of 20-80% solvent B over 5 min at a flow rate of 1.0 ml/min. H3 eluted as a broad complex peak detected by monitoring absorbance at 214 nm. The H3 pool was reduced to dryness in a vacuum centrifuge and then subjected to acid hydrolysis in 6 N HCl at 112 °C for 20 h. A portion of the hydrolyzate was derivatized with *o*-phthaldialdehyde (Jones, B.N., *Methods of Protein Microcharacterization*, J.E. Shively, Ed. (Humana Press, Clifton, NJ, 1986), p. 337) and injected into a 10 cm x 4.6 mm Rainin Microsorb 80OPA-C3 column fitted with a guard module and equilibrated with 95% solvent A (50 mM Na-acetate, pH 5.9: methanol: tetrahydrofuran, 79:20:1) and 5% solvent B (50 mM Na-acetate, pH 5.9:methanol, 20:80) Elution was carried out with a linear gradient of 5-40% B over 20 min at a flow rate of 1.0 ml/min.

5 Radioactivity in the fractions was determined by liquid scintillation counting, and peak identity was determined by comparison to derivatized standards including the three major forms of methylarginine and methyllysine. In addition, another portion of the acid hydrolyzate was subjected to ascending chromatography on thin layers on cellulose using pyridine: acetone: ammonium hydroxide:water (15:9:1.5:6) (Desrosiers, R. and Tanguay (1988) *J. Biol. Chem.* 15 263:4686). Radioactive spots corresponding to the positions of the three forms of methylarginine (which all separated from each other) were removed by scraping the chromatogram, and quantified by liquid scintillation counting. Sources of standards: monomethyl-L-arginine and trimethyl-L-lysine, Calbiochem; N,N'-dimethyl-Larginine and monomethyl-L-lysine, Sigma; N,N-dimethyl-L-arginine, Chemical Dynamics, Corp.; dimethyl-L-lysine, Serva.

20 When histone H3 is methylated by CARM1, hydrolyzed to amino acids, derivatized, and analyzed by high performance liquid chromatography (as described above), all of the radioactivity from histone H3 co-elutes in a single peak along with the derivatized standards of N^G-monomethylarginine and N^G,N^Gdimethylarginine (which did not separate from each other). The radioactive peak was well separated from standards of

25 N^G,N^G-dimethylarginine, N^e-monomethyllysine, N^e-dimethyllysine, and N^e-trimethyllysine. On thin layer chromatography of the hydrolyzate, approximately 70% of the radiolabel migrated with N^G,N^G-dimethylarginine (asymmetrically dimethylated in the guanidino group) and the remaining 30% with N^G-monomethylarginine. In confirmation of the HPLC results, no significant label migrated with N^G,N^G-dimethylarginine (symmetrically dimethylated in the guanidino group).

30 Methylation of mixed histones by PRMT1 was previously shown to produce the same types of

methylated arginine residues (Gary and Clark 1998). However, while they produce the same types of methylated arginine residues, CARM1 and PRMT1 have dramatically different protein substrate specificities (Figure 8 and Table 1). Histone H4, nucleolin, fibrillarin and hnRNPA1, as well as the peptide substrate, all have arginine-containing glycine-rich motifs, whereas histone
5 H3 does not (Najbauer, J. *et al.* 1993; Lin, W-J. *et al.* 1996; Genbank Accession Numbers, for calf thymus histone H3, 70749, and for histone H4, 70762). Thus, it appears that PRMT1 prefers to methylate arginines found in the glycine-rich motifs, whereas CARM1 targets a different arginine-containing motif in proteins.

EXAMPLE 7

10 *Sites of CARM1 methylation of histone H3*

CARM1 methylated the following residues of histone H3, as determined by mass spectrometry analysis: arg2 (minor), arg17 (major), arg26 (major), and one or more of the 4 arginine residues within the histone H3 peptide region comprising residues 128-134. N-terminal sequencing of histone H3 labeled by CARM1-mediated methylation confirmed that within the
15 first 20 amino acids of histone H3, arg2 was a minor methylation site, arg17 was a major methylation site, and arg8 was not methylated (those are the only three arg residues within the first 20 amino acids of H3). The sequencing run was only able to analyze the first 20 amino acids from the N-terminus.

EXAMPLE 8

20 *The role of methyltransferase activity in transcription*

This example show that CARM1's methyltransferase activity is necessary for its activity as a coactivator of transcription. We made a mutation in the CARM1 coding sequences that resulted in replacement of three amino acids, valine 189, leucine 190, and aspartic acid 191, with alanines. This VLD sequence is located in the region that is most highly conserved among
25 different members of the protein arginine methyltransferase family (Figure 1) and is believed to be important for S-adenosylmethionine binding and thus for methyltransferase activity (Lin, W-J. *et al.* (1996) *J. Biol. Chem.* 271:15034-15044). This mutation completely eliminates the ability of the GST-CARM1 fusion protein to methylate mixed histones (Figure 8C) and peptide

substrate R1 (SEQ ID NO:4). The same mutation essentially eliminates CARM1's ability to enhance transcriptional activation by a Gal4DBD-GRIP1_c fusion protein (Figure 6A) or by the estrogen receptor (Figure 6B). Immunoblots of transfected COS7 cell extracts indicated that both wild type and mutant CARM1 were expressed at similar levels. The VLD mutant retains the
5 ability to bind the C-terminal region of GRIP1 (Figure 3B). The correlated loss of the methyltransferase activity and coactivator activity of CARM1 indicates that methyltransferase activity is important for CARM1's coactivator function.

EXAMPLE 9

Synergy of CARM1 with histone acetyl transferases and other protein arginine methyltransferases in transcriptional activation

This example shows that CARM1 and other protein arginine methyltransferases synergistically activate transcription with each other and with histone acetyl transferases. As shown in Figures 9, 10 and 11, cells were transiently transfected with combinations of plasmids encoding GRIP1, CARM1, p300, PRMT1, PRMT2, and PRMT3. At low levels of expression of
15 an appropriate nuclear receptor, in this case estrogen receptor (ER), a combination of GRIP1, CARM1 and p300 are required for activation of the ER-dependent receptor gene (Figure 10B, left side). Similar effects are observed if PRMT1 is substituted for CARM1, other p160 coactivators are substituted for GRIP1, or CBP or P/CAF is substituted for p300. P300, CBP,
10 and P/CAF all have histone acetyltransferase activity. This indicated that histone methyltransferases and histone acetyltransferases have cooperative or synergistic coactivator activity and suggests that methylation and acetylation of histones and/or other proteins in the transcription complex are cooperative processes in the activation of transcription.

The activity of CARM1 is also synergistic with those of PRMT1, PRMT2 or PRMT3. In cells expressing low levels of the orphan (i.e. no ligand) receptor, ERR1 or ERR3,
25 cotransfection of cells with plasmids encoding GRIP1, CARM1 and PRMT1 results in highly increased reporter gene expression as shown in Figure 10A. The synergy between CARM1 and PRMT1 is also observed with three other nuclear receptors: estrogen, androgen, and thyroid

hormone receptors (Figure 9). Figure 11 shows that CARM1 also acts synergistically with either PRMT2 or PRMT3.

Furthermore, due to the very high degree of dependence of the reporter gene activity on the presence of CARM1 and/or PRMT1, these conditions may prove useful for screening for inhibitors of the methyltransferase activity or the coactivator activity associated with these methyltransferases. Such transiently transfected cells when they contain low levels of a nuclear receptor will express the nuclear receptor-dependent reporter gene, in this case luciferase, only in the presence of GRIP1, CARM1 and p300. Molecules that inhibit either the enzymatic activities of these coactivators or the protein-protein interactions of these coactivators would reduce the level of signal from the reporter gene.

EXAMPLE 10

Anti-CARM1 Antibody

The peptide SEQ ID NO: 6: (C)SPMSIPTNTMHYGS-COOH, representing the C-terminal CARM1 amino acid residues 595-608 was coupled to KLH and injected into rabbits.

The (C) is not part of the CARM1 sequence but was added for coupling to KLH. The antiserum was tested at a dilution of 1:2000 in western blotting. The positive control was CARM1 translated in vitro with no radioactive amino acids; the negative control was a parallel in vitro translation reaction with no CARM1 mRNA. Products from these two reactions were separated by molecular weight by SDS-polyacrylamide gel electrophoresis, and the proteins were transferred from the gel to a nylon membrane. The membrane was incubated with the CARM1 antisera, a secondary HRP-coupled antibody, and visualized by luminescence. The positive control gave a very strong band at the expected size for CARM1, while the negative control gave no band at that position.

All of the publications which are cited within the body of the instant specification

are hereby incorporated by reference in their entirety.

TABLE 2. SEQ ID NO: 1. *M. musculuc* cDNA for CARM1 (GenBank Accession No. AF117887).

5	1 agggggcctg gagccggacc taagatggca gcggcgccag cgacggcggt gggccgggt 61 gcggggagcg ctggggtggc gggccgggc ggccggccgc cctgcgtac agtgtctgtg 121 ttcccggcg cccgcctcct cactatcgcc gacgcgaacg gcgagatcca gcggcacgog 181 gaggcaggcagg cgctgcgcct tgaggtgcgc gccggaccag acgcggcggg catgcgcctc 241 tacagccatg aagatgtgtg tggttcaag tgctcggtt cccgagagac agagtgcagt 301 cgtgtggca gacagtccctt catcatacc ctgggctgca acagcgtcct catccagtt 361 gccacacccc acgatttctg ttctttctac aacatctga aaacctgtcg gggccacaca 421 ctggagcgct ctgtgttcag tgagcggaca gaggaaatcct cagctgtgca gtacttccag 481 ttctatggct acctatcccc gacgcagaac atgatgcagg actatgtgcg gacaggcacc 541 taccagcgtg cgatccgtca gaaccacacg gacttcaagg acaagatcgt tctagatgtg 601 ggctgtggct ctggatccct gtcattttt gctgctcaag caggagccag gaaaatttat 661 gcaagtggaaag ccagcaccat ggctcagcat gcagaggtcc tggtaagag taacaatctg 721 acagaccgca tcgtggcat ccctggcaaa gtagaggagg tctcattgcc tgagcaagtg 781 gacattatca tctcagagcc catggctac atgctttca atgaacgaat gctcgagagc 841 tacctccatg ccaaaaagta cctgaagcct agtggaaaca tggcccccac cattggtgat 901 gtccacccctcg cacccttcac tggatgaaacag ctctacatgg agcagttcac caaagccaac 961 ttccggtacc agccatccctt ccatggagtg gacctgtcgg ccctcagagg tgccgctgtg 1021 gatgagttact tccggcaacc tgggtggac acatttgaca tccggatcct gatggccaaa 1081 tctgtcaagt acacagtgaa cttcttagaa gccaaagaag gcgatttgca caggatagaa 1141 atcccatcca aattccacat gctgcattca gggctagttcc atggcttggc cttctgttc 1201 gatgttgctt tcattggctc cataatgacc gttggctat ccacagcccc aacagagccc 1261 ctgacccact ggtaccaggc cccgtgcctc ttccagtcac cttttttgc caaggccggg 1321 gacacgctct caggacatg tctgttattt gccaacaaaa gacagagcta tgacatcagt 1381 attgtggcac aggtggacca gacaggctcc aagtccagta acctgttggc tctaaagaac 1441 cccttcttca ggtacacagg tacaaccccc tcaccccccac ctggctcaca ctacacgtct 1501 ccctcggaga atatgtggaa cacaggaago accttataatc tcagcagcgg ggtggctgtg 1561 gctggaatgc ctactgccta cgacctgago agtggatttgc cccggggctc cagtgtgggt 1621 cacaacaacc tgattccctt agctaacaca gggattgtca atcacaccca ctcccgatg 1681 ggctccataa tgagcacggg cattgtccaa ggctccctcag gtggccaggg aggccggcgg 1741 agtccagtg cccactatgc agtcaacaaac cagttcacca tggtggcccc tgccatctct 1801 atggcctcgc ccatgtccat cccgaccaac accatgcact atgggagttt ggtgcctcca 1861 gccgcgacag cactgcgcac tgacagcacc agggaaaccaa atcaagtcca ggcccggcac 1921 agccagtggc tggcccccct tggcttggag aagttgttga acacccggtc acgcctcct 1981 tggatggaa acttggacaa ttttgcacat gatgtggccg ctggccctcaa gtaccccccag 2041 cccaaacctt ggtcccggc gctgttttgc gccataactt acatgagatc ctgttggggc 2101 agccctcatc ctgttctgtt cttccactc tgacctggct ttgacatctg ctggaaaggagg 2161 caagtccctc cccaaaccccc acagctgcac ctgaccaggc agaggaggc cagcagctgc 2221 caccacagac ctggcagcac ccacccca acccgccctt gcacccccc tcacctgggg 2281 tggcagcaca gccagctgga cctctccctt aactaccagg ccacatggtc accatggcg 2341 tgacatgtg tttttttaa ttttattttt ttacaaaaag aaccagtgtc aacccacaga 2401 ccctctgaga aacccggctg ggcgcaccaag ccagcagccc ctgttccat gcccagaggt 2461 tcttaggtgag ggggtggccct gtcaaggcctt cagatgggc acagccctc ccaccaaagg 2521 gttcacctca aacttgaatg tacaacccac ccagctgtcc aaaggcctag tccctacttt 2581 ctgtctactgt cctgtctga gccctgaagg ccccccctca tcaaaagctt gaacaggcag 2641 cccagagtgt gtcacccctgg gctactgggg cagacaagaa acttcaaaaga tctgtcacac 2701 acacacaagg aaggcgtcct ctccgtatag ctgacatagg cctgtgtt gcttccat 2761 tcatgttctca cttaaatccctc tcaagacagc aaccctggga agagcctcg cagggaccc 2821 cccagacaagg aagaaaagca aacaaggaag ggtgattaat aagcacaaggc agttccct 2881 attcccttac ccttagatcc ccacccatca ggcacccagcc tgccacaggaa accccctggc 2941 aaaggctgga gctgctgtt gccacccctcc tgacctgtca ggaatcaca gggccctcag 3001 gcagctggga accaggctct ctccgttca tcagtaatac tccttgctcg gatggccctc 3061 ccccacctt atataaattt tctggatcac ctttgcatac aaaataaaag tggggcttt 3121 gtaa
---	--

TABLE 3. SEQ ID NO: 2. Dduced amino acid sequence of CARM1 (GenBank Accession No. AAD41265).

```

5   1 maaaaatavg pgagsagvag pggagpcatv svfpgarllt igdangeiqr haeqqalrle
    61 vragpdaagi alyshedvcv fkcsvsrete csrvgrqsfi itlgcnsli qfatphdfcs
    121 fynilktcrg htlersvfse rteessavqy fqfygylsqq qnmmqdyvrt gtyqrailqn
    181 htdfkdkivl dvgcgsgils ffaaqagark iyaveastma qhaevlvksn nltdrivip
    241 gkveevs1pe qvdiiisepm gymlfnerml esylhakkyl kpsgnmfpti gdvhlapftd
    301 eqlymegftk anfryqpsfh gvdl salrga avdeyfrqpv vdtfdi rilm aksvkytvnf
    361 leakage dhlhr ieipfkfml hsglvhglaf wfdvaf figsi mtvw lstapt eplthwyqvr
    421 clfq splfak agdt lsgtcl liankr qsyd isivaqv dgt gskssn lldl knpffrytgt
    481 tpspppgshy tpsenmwnt g stynl ssgv avagmptayd lssviaggss vghnnlipla
    541 ntgivnhths rmgsimstgi vqgssgaqgg ggsssa hyav nnqftmggpa ismaspmsip
    601 nt mhygs
15

```

TABLE 4. SEQ ID NO: 3. Sequence of CARM1 VLD to AAA variant.

```

20  1 maaaaatavg pgagsagvag pggagpcatv svfpgarllt igdangeiqr haeqqalrle
    61 vragpdaagi alyshedvcv fkcsvsrete csrvgrqsfi itlgcnsli qfatphdfcs
    121 fynilktcrg htlersvfse rteessavqy fqfygylsqq qnmmqdyvrt gtyqrailqn
    181 htdfkdkiaa avgcgsgils ffaaqagark iyaveastma qhaevlvksn nltdrivip
    241 gkveevs1pe qvdiiisepm gymlfnerml esylhakkyl kpsgnmfpti gdvhlapftd
    301 eqlymegftk anfryqpsfh gvdl salrga avdeyfrqpv vdtfdi rilm aksvkytvnf
    361 leakage dhlhr ieipfkfml hsglvhglaf wfdvaf figsi mtvw lstapt eplthwyqvr
    421 clfq splfak agdt lsgtcl liankr qsyd isivaqv dgt gskssn lldl knpffrytgt
    481 tpspppgshy tpsenmwnt g stynl ssgv avagmptayd lssviaggss vghnnlipla
    541 ntgivnhths rmgsimstgi vqgssgaqgg ggsssa hyav nnqftmggpa ismaspmsip
    601 nt mhygs
30

```

TABLE 5. SEQ ID NOS: 4 and 5. Peptides used for *in vitro* methylation experiments.

R1 peptide	SEQ ID NO: 4	GGFGGRRGGFG
K1 peptide	SEQ ID NO: 5	GGFGGKGGFG

TABLE 6. SEQ ID NO: 6. Peptide used to generate anti-CARM1 antisera.

SEQ ID NO: 6: CSPMSIPTNTMHYGS

TABLE 7. SEQ ID NO: 7. Human PRMT1 (GenBank Accession No. CAA71765).

```

45  1 mevscgqaes sekpnnaedmt skdyyfdSYA hfgiheemlk devrtltyrn smfhnrhlfk
    61 dkvvldvgsg tgilcmfaak agarkvигив cssisdyavk ivkankldhv vtiikgkvee
    121 velpvekvdi iisewmgycl fyesmlntvl yardkwlapd glifpdratl yvtaiedrqy
    181 kdykihwwen vygfdmscik dvaikeplvd vvdpkqlvtn aclikeydiy tvkvedltft
    241 spfc1qvkrn dyvhalvayf nieftrchkr tgfstspsesp ythwkqtvfy medyltvktg
    301 eeifgtigmr pnaknnrdld ftidldfkqgq lcelscstdy rmr

```

TABLE 8. SEQ ID NO: 8. Human PRMT2 (GenBank Accession No. CAA67599)

5 1 matsgdcpes esqgeepaec seagllqegv qpeefvaiad yaatdetqls flrgekilil
61 rqttadwwwg eragccgyip anhvgkhvde ydpedtwqde eyfgsygtlk lhlemladqp
121 rttkyhsvil qnkesldkv ildvgcgtgi islfcahyar pravyaveas emaqhtgqlv
181 lqngfadiit vyqqkvedvv lpekvndlvs ewmgtcllfe fmiesilyar dawlkedgvi
241 wptmaahlv pcsadkdyrs kvlwdnaye fnlsalksla vkeffskpkv nhlkpedcl
10 301 sepctilqlq mrtvqisdlr tlrgerfdi rkagtlhgft awfsvhfqsl qeqgppqvls
361 tgpfhptthw kqtlfmmddp vpvtgdvvt gsvvqlqrnpv wrrhmsvals wavtsrqdpt
421 sqkvgekvfp iwr

TABLE 9. SEQ ID NO: 9. Human PRMT3 (GenBank Accession No. AAC39837)

15 1 depelsdsgd eaaweddedda dlphgkqgtp clfcnrlfts aeetfshcks ehqfnidsmv
61 hkhglefygy iklinfirlk nptveymnsi ynpvpwekee ylkpvleddl llqfdvedly
121 epvsvpfsyp nglentsvv eklkhmeara lsaeaalara redlqkmkqf aqdfvmhtdv
181 rtcssstsvi adlqededgv yfssyghygi heemlkdkir tesyrdfiyq nphifkdvv
241 ldvgcgtgil smfaakagak kvlvdqsei lyqamdiirl nkledtitli kgkieevhlp
20 301 vekvvdviise wmgylflifes mldsvlyakn kylakggsvy pdictislvva vsdvnkhadr
361 iafwddvygf kmscmkkavi peavvevldp ktlisepcqi khidchttsi sdlefssdft
421 lkirttsmct aiagyfdiyf eknchnrvvf stgpqstkth wkqtvfllek pfsvkageal
481 kgkvvhknk kdprsltvrl tlnnstqtyg lq

TABLE 10. SEQ ID NO: 10. Yeast ODP1 Protein Arginine Methyltransferase. (GenBank Accession No. 6319508)

30 1 msktavkdsa tektklsese qhyfnisydhy giheemlqdt vrtlsyrnai iqnkdlfkdk
61 ivldvgcgtg ilsmfaahg akhvigvdms siiemakelv elngfsdkit llrgkledvh
121 lpfpkvdii sewmgylly esmmtdtvya rdhylveggl ifpdksihl agledsqykd
181 eklnywqdyv gfdyspfvpl vlhepivdtv ernnvnttsd kliefdlntv kisdlafksn
241 fkltakrqdm ingivtwfdi vfpapkgkrp vefstgphap ythwkqtify fpddldaetg
35 301 dtiegelvcs pneknrndln ikisykfesn gidgnrsrpk negsylmh

CLAIMS

What is claimed is:

1. An isolated nucleic acid molecule comprising a sequence substantially equivalent to that of SEQ ID NO: 1 or a fragment thereof having at least about 40 nucleotides.
2. A recombinant vector comprising the nucleic acid molecule of claim 1.
3. A genetically engineered cell comprising the recombinant vector of claim 2.
4. An isolated polypeptide comprising an amino acid sequence substantially equivalent to that of SEQ ID NO: 2 or a fragment thereof.
5. The isolated polypeptide of claim 4 further comprising a purification domain.
6. The isolated polypeptide of claim 5 wherein said purification domain is gluathione-S-transferase.
7. The isolated polypeptide of claim 4 further comprising a DNA binding domain.
8. The isolated polypeptide of claim 7 wherein said DNA binding domain is the Gal4 DNA binding domain.
9. The isolated polypeptide of claim 4 further comprising a transcription activation domain.
10. The isolated polypeptide of claim 9 wherein said transcription activation domain is the Gal4 transcription activation domain.
11. The isolated polypeptide of claim 4 wherein said peptide substantially lacks methyltransferase activity, but retains the ability to bind to p160 proteins.

12. The isolated polypeptide of claim 11 wherein the substitution of residues 189, 190, and 191 of SEQ ID NO: 2 result in the substantial lack of methyltransferase activity and retention of p160 binding ability.

13. The isolated polypeptide of claim 12 which has the amino acid sequence of SEQ ID NO: 3 or a fragment thereof.

14. An antibody directed towards the isolated polypeptide of claim 4.

15. The antibody of claim 14 wherein said antibody is monoclonal.

16. The antibody of claim 14 wherein said antibody is polyclonal.

17. A method for methylating amino acid residues within a substrate polypeptide comprising contacting the polypeptide of claim 4 with said substrate polypeptide in the presence of S-adenosylmethionine.

18. The method of claim 17 wherein said substrate amino acid residue that is methylated is arginine.

19. The method of claim 17 wherein said substrate polypeptide is a histone.

20. The method of claim 19 wherein said histone is histone H3.

21. A methylated histone H3 or fragment thereof produced according to the method of claim 17.

22. An antibody directed towards the methylated histone of claim 21.

23. A method for screening for molecules that modulate an interaction between CARM1 and GRIP-1 comprising:

expressing within a host cell a first recombinant protein comprising SEQ ID NO: 2 or a fragment thereof fused to a first interaction domain;

expressing within said host cell a second recombinant protein comprising a CARM1-interacting protein or fragment thereof fused to a second interaction domain;

providing in said host cell a reporter gene construct comprising a reporter gene and a promoter region which interacts with either said first interaction domain or said second interaction domain and wherein said first recombinant protein and said second recombinant protein interact with sufficient affinity to facilitate expression of said reporter gene; and

measuring said reporter gene expression level in the presence of a modulating molecule.

24. The method of claim 23 wherein said first interaction domain is a DNA binding domain and said second interaction domain is a transcriptional activation domain.

25. The method of claim 23 wherein said first interaction domain is a transcriptional activation domain and said second interaction domain is a DNA binding domain.

26. The method of claim 23 wherein said reporter gene construct comprises a nucleic acid molecule encoding β -galactosidase, green fluorescent protein, luciferase or β -lactamase.

27. A method for modulating expression of a nuclear receptor-dependent gene in a cell comprising:

expressing in said cell a first nucleic acid molecule encoding a protein arginine methyltransferase;

expressing in said cell a second nucleic acid molecule encoding a p160 coactivator; and

wherein the co-expression of said first and said second nucleic acid molecules modulates the expression level of said nuclear receptor-dependent gene.

28. The method of claim 27 wherein said protein arginine methyltransferase is CARM1, PRMT1, PRMT2 or PRMT3.

29. The method of claim 28 further comprising expressing a second protein arginine methyltransferase.

30. The method of claim 29 wherein said first protein arginine methyltransferase is CARM1.

31. The method of claim 30 wherein said second protein arginine methyltransferase is PRMT1, PRMT2 or PRMT3.

32. The method of claim 28 further comprising expressing a second coactivator wherein said second coactivator possesses histone acetyltransferase activity.

33. The method of claim 32 wherein said second coactivator is CBP, P/CAF or p300.

34. A method for screening of molecules that modulate CARM1 coactivator activity in a cell comprising:

expressing in said cell a nuclear receptor-dependent reporter gene;

expressing in said cell CARM1;

expressing in said cell a p160 coactivator;

expressing in said cell a second coactivator with histone acetyltransferase activity or a second protein arginine methyltransferase;

expressing in said cell a nuclear receptor gene, wherein said nuclear receptor gene is expressed at a level such that expression of said reporter gene is at least about 10-fold higher than in a cell not expressing either CARM1, a p160 coactivator, or either a second coactivator or a second protein arginine methyltransferase; and

comparing the expression levels of said reporter gene in said cell in the presence and absence of a modulating compound.

35. The method of claim 34 wherein said p160 coactivator is GRIP1, SRC-1 or p/CIP.

36. The method of claim 35 wherein said p160 coactivator is GRIP1.

37. The method of claim 35 wherein said second coactivator is p300, CBP or p/CAF.

38. The method of claim 35 wherein said second protein arginine methyltransferase is PRMT1, PRMT2 or PRMT3.

ABSTRACT

The invention relates to the cDNA and deduced amino acid sequence of the Coactivator Associated arginine (R) Methyltransferase protein, CARM1. A method is described for the use CARM1 to regulate gene expression *in vivo*. CARM1 has also been used to methylate arginine residues of histones, synthetic peptides, and other proteins. A method to use CARM1 to screen for drugs that inhibit its methyltransferase activity is also described, as is a method to screen for drugs that modulate CARM1's interactions with other proteins.

Figure 1

SEQ ID NO:1	CARM1	168	VRTGTYQRAILQNHTDFKDKIVLDVGCGSGILSFFAAQAG.ARKIYAVEASTMAQHAEVL	226
SEQ ID NO:3	CARM1	168	VRTGTYQRAILQNHTDFKDKIAAAVGCNSGILSFFAAQAG.ARKIYAVEASTMAQHAEVL	226
SEQ ID NO:7	hPRMT1	52	---L--RNSMFH-RHL----V-----S-T---CM---K---.---VIGI-C-SISDY-VKI	111
SEQ ID NO:8	hPRMT2	120	P--TK-HSV---KESLT--VI-----T-----L-C-HYARP-AV-----E---TGQ-	179
SEQ ID NO:9	hPRMT3	219	I--ES-RDF-Y--PHI-----V-----T-----M---K--.---K-VLG-DQ-EILYQ-MDI	277
SEQ ID NO:10	yODP1	41	---LS-RN-----KDL-----T-----M---KH-.---KHVIG-DM-SIIEM-KE-	99

SEQ ID NO:1	CARM1	227	VKSNNLTDRIVVIPGKVEEVSLP.EQVDIIIISEPMGYMLFNERMLESYLNHAK.KYLKPSG	284
SEQ ID NO:3	CARM1	227	VKSNNLTDRIVVIPGKVEEVSLP.EQVDIIIISEPMGYMLFNERMLESYLNHAK.KYLKPSG	284
SEQ ID NO:7	hPRMT1	112	--A-K-DHVVTI-K-----E--V-K-----W--C-Y-S---NTV---RD-W-A-D-	171
SEQ ID NO:8	hPRMT2	180	-LQ-GFA-I-T-YQQ---D-V--.---K--VLV--W--TC-LF-F-I--I-Y-RDAW--ED-	238
SEQ ID NO:9	hPRMT3	278	IRL-K-E-T-TL-K-I---H--V-K--V-----W---F-LF-S--D-V-Y--N---AKG-	337
SEQ ID NO:10	yODP1	100	-EL-GFS-K-TLLR-L--D-H--FPK-----W---F-LY-S-MDTV-Y-RDH--VEG-	159

FIGURE 2




FIGURE 3




FIGURE 4





FIGURE 5

A



B




FIGURE 6




FIGURE 7

Model: a Role for Protein Methylation in Transcriptional Regulation




FIGURE 8

Protein Methyltransferase Activity




FIGURE 9





FIGURE 10

A



B

Synergy among three coactivators with different levels of ER






FIGURE 11



United States Patent & Trademark Office
Office of Initial Patent Examination – Scanning Division



Application deficiencies were found during scanning:

Page(s) _____ of _____ were not present
for scanning. (Document title)

Page(s) _____ of _____ were not present
for scanning. (Document title)

*There are 53 pages of specification not
scanned.*

Scanned copy is best available.